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Abstract 5 
Biliary disorders are the leading indication for pediatric liver transplantation due to the lack of alternative 6 
treatments for repairing or replacing damaged bile ducts. To address this challenge, we developed a 7 
protocol for generating bioengineered biliary tissue suitable for biliary reconstruction. Our platform 8 
allows the derivation of cholangiocyte-organoids (COs) expressing key biliary markers and function 9 
from primary extra- or intrahepatic duct cholangiocytes, within 2 weeks of isolation. COs are 10 
subsequently seeded on Poly-Glycolic Acid scaffolds or densified collagen constructs for 4 weeks to 11 
generate bioengineered tissue retaining biliary characteristics. Therefore, expertise in organoid culture 12 
and tissue-engineering are desirable for optimal results. Importantly, COs correspond to mature 13 
functional cholangiocytes, differentiating our method from alternative organoid systems propagating 14 
adult stem cells. Consequently, COs provide a unique platform for studies in biliary physiology and 15 
pathophysiology; while the resulting bioengineered tissue has broad applications for regenerative 16 
medicine and cholangiopathies.  17 
 18 











Cholangiopathies comprise a diverse group of disorders characterized by damage to the biliary tree 2 
and loss of bile ducts resulting in cholestasis, hepatic injury and ultimately liver failure1,2. However, 3 
treatment options are limited to liver transplantation. Indeed, biliary disease remains the leading 4 
indication for this intervention in children, with more than 70% of paediatric liver grafts being used to 5 
treat biliary atresia3. The generation of healthy biliary tissue suitable for replacing or reconstructing 6 
damaged bile ducts could address the clinical need for alternative therapeutic approaches and reduce 7 
pressure on the transplant waiting list. However, progress in this area has been hampered by 8 
challenges in long-term culture and large-scale expansion of primary cholangiocytes. Here, we describe 9 
a protocol for the fabrication of functional bioengineered biliary tissue, using biocompatible and 10 
biodegradable scaffolds and a novel method for the isolation and propagation of primary cholangiocytes 11 
in organoid format. 12 
 13 
Development of the protocol 14 
To generate bioengineered biliary tissue suitable for surgical manipulation and biliary reconstruction, 15 
we decided to combine primary biliary epithelium with appropriate matrices. 16 
Development of the protocol for cholangiocyte organoid culture 17 
First, we developed a culture protocol for the propagation and large-scale expansion of primary adult, 18 
functional cholangiocytes4. Because biliary reconstruction is predominantly performed on the common 19 
bile duct (CBD), we initially focused on the isolation of CBD cholangiocytes using excised bile ducts 20 
from deceased organ donors. To achieve expansion of the isolated cholangiocytes, the cells were 21 
embedded in Matrigel and treated with a combination of EGF, R-Spondin-1 and DKK-1. We have 22 
previously demonstrated that the combination of EGF and 3D culture can promote limited growth of 23 
partially mature, foetal CLC organoids derived from iPS5,6, while primary adult stem cell organoids have 24 
been isolated from murine biliary tissue7. To support the long-term expansion of adult cholangiocytes 25 
we used R-spondin-1, a WNT agonist reported to stimulate organoid derivation from multiple adult 26 
epithelia 8-13. However, R-spondin promotes the propagation of adult stem cells rather than mature 27 
epithelial populations by enhancing canonical Wnt signalling 14. To avoid the amplification of adult stem 28 
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cells, we introduced DKK-115, a canonical WNT/β-catenin pathway antagonist 16,17. When used in 1 
combination with R-spondin, DKK-1 inhibits canonical and enhances non-canonical WNT signalling 2 
though the planar cell polarity (PCP) pathway 4, which has been reported to play a role in cholangiocyte 3 
maturation 18,19. The combination of EGF, R-Spondin-1 and DKK-1 allowed for long-term, large-scale 4 
expansion of functional, genetically stable, primary adult cholangiocyte organoids (COs).  5 
Our system was developed and optimized for the culture of CBD cholangiocyte organoids, isolated from 6 
fresh excised bile ducts. However, this isolation method depends on a major complex operation, thereby 7 
posing significant limitations related with access to biliary tissue. To overcome this issue, we 8 
subsequently validated the capacity of our culture system for the derivation of cholangiocyte organoids 9 
from multiple sources such as excised gallbladders, endoscopic retrograde cholangiopancreatography 10 
(ERCP) brushings and liver biopsy samples. Using this platform cholangiocyte organoids can be 11 
isolated and expanded using samples from any area of the biliary tree acquired by any of these isolation 12 
methods. 13 
Choice of scaffolds 14 
Our next goal was to identify appropriate scaffolds that could be combined with the cells to generate 15 
tissue-like constructs. Important considerations for the choice of scaffolds were their potential to support 16 
growth of the cells, their capacity to be integrated to the host tissue following transplantation with 17 
minimal inflammatory response and the use of biodegradable materials allowing for tissue remodelling 18 
which is crucial for neo-vascularization. Furthermore, to support future clinical translation, the materials 19 
used should be compatible with human transplantation. 20 
Importantly, both synthetic and biological polymer scaffolds with these specifications are available. 21 
Since there are advantages and disadvantages associated with each approach, we decided to explore 22 
both. Synthetic polymer scaffolds are widely used as they can be easily processed using a wide range 23 
of techniques and adapted for multiple tissue engineering applications 20. They have tuneable and 24 
reproducible physicochemical properties, mechanical strength, and degradation rates, making them 25 
highly customisable as a scaffold material 20,21. Biological polymer scaffolds are more challenging to 26 
tailor to a particular application owing to purity issues, immunogenicity, and scaffold homogeneity and 27 
reproducibility 22. However biological polymer scaffolds have superior bioactive properties (e.g. cell 28 
attachment, migration, cell scaffold remodelling) and thus better cell and tissue interactions 22,23. 29 
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Generation of bioengineered tissue using synthetic scaffolds 1 
First, we focused on synthetic scaffolds commercially available ‘off the shelf’, to optimize cell seeding, 2 
attachment and culture of the resulting tissue. We decided to use a Poly-Glycolic Acid (PGA) matrix 3 
due to its biodegradability, flexibility and lack of inflammatory response in vivo24. Additionally, synthetic 4 
PGA scaffolds can be easily processed into tailored architectures 22,23. For these reasons, PGA is one 5 
of the most commonly used synthetic polymers in tissue engineering21 and has been approved by the 6 
FDA for use in human studies25.  7 
We subsequently identified the optimal method for seeding COs on the scaffolds. Our results 8 
demonstrated the use of cell clumps concentrated in small volumes to be the optimal seeding method. 9 
Indeed, the dissociation of organoids into single cells requires aggressive enzymatic digestion. This 10 
approach reduces cell viability and attachment due to the cleavage of multiple cell-to-matrix adhesion 11 
molecules26. Furthermore, small volumes of cell suspension are absorbed by the scaffold, maximizing 12 
cell to scaffold contact. This technique resulted in the generation of confluent PGA-scaffolds seeded 13 
with COs, which were used to successfully repair biliary tree wall defects in immunocompromised mice, 14 
following transplantation. 15 
Generation of bioengineered tissue using biological scaffolds 16 
We subsequently used the same seeding methodology to populate biological scaffolds. Here we chose 17 
densified collagen hydrogel due to its biocompatibility, low immunogenicity, ability to favour cell 18 
attachment and growth, biodegradability, and ability to be naturally remodelled by cells 27. Importantly, 19 
unlike standard collagen gel, densified collagen demonstrates superior mechanical properties for 20 
surgical applications27,28. Densification expels the majority of the water content of the collagen gel, vastly 21 
reducing its volume, resulting in a polymer scaffold of higher concentration and fibrillar alignment 28. 22 
Through the use of appropriate moulds, the densification process can be customized to generate 23 
constructs of more complex geometries, which can be successfully seeded with COs.  24 
Generation of bioengineered mouse bile ducts 25 
One of the most relevant clinical applications of bioengineered biliary tissue is the generation of tubular 26 
constructs suitable for biliary reconstruction. However, bile duct transplantation can be associated with 27 
significant inflammatory response, epithelial damage and formation of anastomotic strictures in humans 28 
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29,30. Consequently, in vivo validation of the function, biocompatibility and patency of bioengineered 1 
ducts following reconstruction is required. To achieve this goal, we decided to generate bioengineered 2 
constructs populated with human COs, transplant them in immunocompromised mice and characterise 3 
them.  4 
A key challenge was the fabrication of tubular structures with dimensions comparable to the mouse 5 
CBD (250 µm inner diameter and 30 µm wall thickness). Indeed, commercially-available fibrous PGA 6 
scaffolds31 were incompatible with these requirements due to a minimum thickness (300 µm) 7 
significantly larger than the required wall thickness. Appropriate thickness pre-densified collagen gel 8 
sheets could be fashioned into a tube using sutures; however, interruption of the collagen fibrils along 9 
the seam led to partial collapse of the lumen under the weight of the wall. To overcome these 10 
challenges, a method was developed in which collagen was cast around a central rod and densified 11 
afterwards, to yield a seamless tube with a thin and robust wall. Furthermore, a conical funnel mould 12 
was used which allowed a proportionately large volume of collagen to densify into a short length of tube 13 
and enabled efficient water removal via multiple routes (through on-axis absorption and radial 14 
evaporation). These techniques yielded bioengineered tubes with a patent lumen and dimensions 15 
similar to the mouse CBD. 16 
We subsequently used the approach we developed for seeding COs on flat collagen scaffolds to seed 17 
the luminar surface of the construct with cells and generate mouse-sized bioengineered bile ducts 18 
populated with human cells. Importantly, the potential of these constructs for biliary reconstruction in 19 
vivo was illustrated through their successful transplantation in immunocompromised mice4.  20 
 21 
Applications and target audience 22 
The propagation of cholangiocyte organoids and generation of bioengineered biliary tissue is likely to 23 
be of interest to a broad scientific audience including clinician scientists focusing on translation of new 24 
therapies to clinic, bioengineers working on whole organ reconstruction, groups focusing on biliary 25 
physiology and disease and the pharmaceutical industry. Currently the only therapeutic option for biliary 26 
disorders is liver transplantation. The generation of bioengineered biliary tissue could provide one of 27 
the first alternative treatments and pioneer the use of regenerative medicine for cholangiopathies 32,33. 28 
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Furthermore, a limitation of complex liver co-culture systems is the lack of a biliary system. The capacity 1 
of cholangiocyte organoids to grow in a variety of matrices and scaffolds makes them an ideal addition 2 
for complex tissue engineering applications that focus on recapitulating the microanatomy of the liver 3 
and the development of artificial whole-organ systems. 4 
Cholangiocytes constitute a rare liver cell type and access to primary tissue has limited large scale 5 
analyses in the past. Cholangiocyte organoids resemble primary biliary epithelium very closely in terms 6 
of transcriptional profile and function 4. Consequently, extrahepatic COs (ECOs) and intrahepatic (ICOs) 7 
could serve as a surrogate for primary cholangiocytes from any region of the biliary tree, enabling in 8 
depth, large scale studies of biliary physiology and pathophysiology. Similarly, COs recapitulate the 9 
effects of compounds such as verapamil or somatostatin, rendering them suitable for drug screening 10 
applications. 11 
 12 
Comparison to other methods  13 
A unique feature of our culture system is that it enables the long-term culture of mature cholangiocytes 14 
through the inhibition of canonical WNT signalling by DKK-1, maintaining adult characteristics and 15 
functionality with no need for additional differentiation. Therefore, our system is distinct to alternative 16 
primary organoid platforms based on canonical WNT signalling which propagate adult stem cells 8,11,13,34 17 
rather than bona-fide biliary epithelium. Consequently, COs may be better suited for studies on biliary 18 
physiology and disease requiring high fidelity cholangiocytes, while adult stem cells are optimal for 19 
studies on liver repair and regeneration. 20 
While methods for short-term culture of murine35 and human primary cholangiocytes have been 21 
reported 36,37, these systems are technically challenging, only allow for limited expansion restricting 22 
large scale analyses and the function of the resulting cells has not been extensively characterized. COs 23 
combine high proliferative capacity, increased functionality and the potential for large scale expansion, 24 
which is crucial for regenerative medicine or for high-throughput applications.  25 
Importantly, cholangiocytes can be derived from induced pluripotent stem cells 5,6,38,39. However, these 26 
cells correspond to fetal intrahepatic cholangiocytes, whereas our method can generate both 27 
intrahepatic and extrahepatic adult cholangiocytes. Additionally, COs can be rapidly isolated and 28 
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expanded, unlike iPSC systems which require a lengthy differentiation process and cannot be further 1 
propagated once terminally differentiated. Consequently, stem cell derived cholangiocytes are optimal 2 
for studies on intrahepatic bile duct development and its disorders, while COs are better suited for 3 
studies of adult intra- and extra-hepatic cholangiocyte physiology or regenerative medicine applications 4 
requiring large numbers of highly functional cells in little time. 5 
Our system provides multiple advantages for tissue engineering and regenerative medicine. The 6 
generation of bioengineered tissue is versatile, allowing the use of synthetic (PGA) or biological 7 
scaffolds (collagen). Furthermore, it is compatible with GMP-compliant materials, such as collagen 8 
which has an excellent in vivo profile and is used extensively in clinical applications 24. The method by 9 
which the densified collagen tubes are formed allows their generation at customisable length-scales 10 
compatible with small animal studies. Further, the densification process does not impart significant 11 
stress upon the cells, which can be mixed in the gel if required. The resulting constructs can be 12 
maintained more than 2 months in culture enabling the generation of large batches of bioengineered 13 
tissue with prolonged ‘shelf-life’. Importantly, our bioengineered biliary tissue provides the first proof-of-14 
principle for organ reconstruction using primary epithelial organoids, where the resulting bioengineered 15 
construct was used to fully replace the native organ 4.  16 
 17 
Limitations 18 
A limitation of our system is that COs, as adult primary cholangiocytes, are not suitable for studying 19 
biliary development, an application for which stem cell derived systems are more appropriate. 20 
Additionally, as COs represent a pure epithelial population, this system does not currently allow for the 21 
study of epithelial and mesenchymal interactions, although the potential exists within our system to 22 
generate bioengineered tissue with additional cell types. A further, technical, limitation is that COs 23 
currently rely on the use of Matrigel, a non-GMP-compliant extracellular matrix. However, multiple 24 
chemically defined hydrogel matrices, which could replace Matrigel, are currently in development 40.  25 
 For research groups without access to a hospital with hepatobiliary services access to primary tissue 26 
may present a challenge, as primary samples need to be processed promptly following isolation. We 27 
note that samples can be obtained in any hospital that offers a cholecystectomy, ERCP or liver biopsy 28 
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service and organoid derivation is still feasible after small delays associated with tissue transfer over 1 
short distances. Nevertheless, to compensate for transport associated delays when multiple samples 2 
from distal centres are processed, a team of trained technicians working in parallel may be required.  3 
Finally, although mouse-sized (submillimetre) constructs serve as proof-of-principle for the generation 4 
of bioengineered ducts populated with human cells, their mechanical properties do not translate to those 5 
of the human bile duct (7mm diameter, 1mm wall thickness). Therefore, optimisation of our technique 6 
for the generation of human sized constructs with appropriate physical attributes will be required prior 7 
to clinical translation.  8 
 9 
Experimental design 10 
Our method describes a system for isolating primary extrahepatic and intrahepatic cholangiocytes from 11 
primary tissue, culturing these primary cholangiocytes in a 3D organoid system and generating 12 
bioengineered biliary tissue using artificial scaffolds (Figure 1). In this section we describe infrastructure 13 
and experimental setup considerations that need to be taken into account prior utilising this protocol.  14 
Isolation of cholangiocytes from primary tissue 15 
Our protocol requires the isolation of cholangiocytes from primary human tissue, either from living 16 
patients or deceased organ donors. As such, appropriate ethical approval from the relevant regulatory 17 
bodies is required, while informed consent is essential prior to acquiring any human tissue samples.  18 
Obtaining fresh human tissue samples will require access to a hospital with one of the following 19 
services:  hepatology, advanced endoscopy, hepatobiliary surgery, transplant organ procurement or 20 
liver transplantation. Importantly, donor tissue viability decreases proportionally to ex-vivo storage and 21 
bile exposure. Therefore, tissue must be flushed from bile and stored immediately in cold preservation 22 
solution (such as University of Wisconsin (UW) solution) or supplemented William’s E+ media) at 4 °C 23 
until it can be processed 41.  24 
 When multiple tissue samples are obtained simultaneously (such as from a deceased organ donor), 25 
the tissue should be processed in order of sensitivity to cold storage (supplemental figure 1). Liver 26 
biopsies require immediate processing, while extrahepatic tissue can be stored at 4 °C for several 27 
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hours, provided it is appropriately flushed of bile. Furthermore, all tissue handling should be performed 1 
under aseptic conditions to avoid contamination. Consequently, good communication with the clinicians 2 
obtaining the sample is crucial. Long-distance transport of samples is likely to impact the viability of 3 
explanted tissue, so samples must ideally be processed in a facility close to the site of collection. Tissue 4 
must be processed in a category 2 tissue culture hood under aseptic conditions and sterile surgical 5 
equipment must be used.  6 
CO lines can be generated using multiple approaches, depending on the source of available tissue and 7 
the method of sample collection (Fig. 1). Surgically excised tissue samples such as gallbladders and 8 
bile ducts can be used for the generation of COs following isolation of the luminal layer of cholangiocytes 9 
through mechanical scraping (Fig. 2a-e). Endoscopic Retrograde Cholangiopancreatography (ERCP) 10 
brushings provide an alternative source of tissue for patients having endoscopy (Fig. 3a-d). Isolation of 11 
COs from liver biopsy tissue can be performed by dividing a liver biopsy core into small pieces 12 
(approximately 1 mm3) and plating them directly in CO organoid culture conditions (Fig. 4a-e). 13 
Alternatively, CO lines can be derived from a population of EpCAM+ sorted single cells (Supplementary 14 
Fig. 2a-c). Tissue can be enzymatically digested to a single-cell suspension and then EpCAM+ sorted 15 
through either FACS or MACS.  16 
Provided the tissue has been appropriately and promptly processed, the methods described should 17 
produce CO lines with almost 100% efficiency, apart from EpCAM+ sorting, which yields viable lines 18 
with an efficacy of 66% (supplementary table 1) due to the impact of single cell dissociation on cell 19 
viability. Flushing the tissue of bile is crucial to achieving these results. Indeed, derivation efficiency is 20 
reduced from 95% to to 40% if flushing is not performed (supplementary table 1). The optimal technique 21 
for CO line derivation should be decided based on sample availability and access to tissue.  22 
Establishment and maintenance of cholangiocyte organoids 23 
Once plated, primary cholangiocytes should form organoids in 3-10 days. Clump size and seeding 24 
density can affect the speed and efficiency of derivation. Single cells tend to require longer culture and 25 
yield lower numbers of organoids for the same number of starting cells. Large clumps of >50-100 cells 26 
and high seeding density may result in cell attachment and limit organoid growth. 27 
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CO lines should be passaged approximately every five days (Fig. 5a-b), although the cells should be 1 
monitored daily for reaching confluency (Fig. 5b, Supplementary Fig. 3). Delays in passaging confluent 2 
wells can result in organoid collapse and affect the long-term health of the organoid line (Supplementary 3 
Fig. 4b). The same considerations as for organoid derivation apply with regards to clump size and 4 
seeding density during passaging (Supplementary Fig. 4b). Importantly, our protocol relies on Matrigel 5 
as an extracellular matrix which has a profound impact on the quality of the resulting organoid lines. 6 
Therefore, Matrigel must be batch tested before use. It is also important to ensure that all reagents and 7 
media used in the maintenance of CO lines are not used for longer than three months as this can impact 8 
on organoid quality.  9 
Organoids can be analysed through a variety of methods such as qPCR, immunofluorescence and flow 10 
cytometry, as we have previously described 5,6. COs should show robust expression of key biliary 11 
markers such as cytokeratin 19, cytokeratin 7, Sox9 and gamma-glutamyl transferase (GGT), as well 12 
as key cholangiocyte functions such as alkaline phosphatase (ALP) and GGT activity (Fig. 6a-e), which 13 
can be used to assess the quality of CO derivation and culture.  14 
Scaffold preparation 15 
Bioengineered tissue can be generated using both synthetic (PGA) and biological (densified collagen 16 
gel) polymeric scaffolds, each of which may be suited to different applications. PGA scaffolds can be 17 
commercially sourced, are cheap, and require minimal processing to yield positive results. The 18 
mechanical properties of the scaffold (e.g. Young’s modulus, strength) are tuneable and can be 19 
customized by adjusting density and pore size. Furthermore PGA constructs can be easily fabricated 20 
into custom architectures 22,23.  21 
Collagen constitutes a physiological component of the extracellular matrix 42 with high bioactivity 43 22 
which can interact with cells and present multiple cues that enhance attachment, survival, proliferation 23 
and tissue remodelling 42,44. Furthermore, unlike PGA, cells may be mixed directly into the collagen gel 24 
precursor solution prior to gelation and densification, generating a uniform network of cells throughout 25 
the scaffold, which is useful for applications such as complex co-culture systems. However, it is more 26 
expensive than synthetic alternatives and scaffolds with adequate mechanical strength for surgical 27 
manipulation 45,46 are not commercially available and need to be custom made. Indeed, densified 28 
collagen sheets need to be fabricated from collagen gels through water absorption (figure 7a-b); while 29 
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densified collagen tubes, need to be formed through moulding of collagen gel around a cylindrical 1 
template and water removal by evaporation from the gel surface (figure 8a-d). Consequently, densified 2 
collagen scaffolds are more physiological but require a higher level of expertise and pose a greater 3 
number of potential pitfalls, while PGA scaffolds may be appropriate for settings where the expertise 4 
and equipment for the generation of custom-made scaffolds are not available. 5 
Scaffold seeding 6 
PGA and densified collagen scaffolds (both flat and tubular) can be seeded with COs to generate 7 
bioengineered biliary tissue within 2-4 weeks. The cells are seeded as clumps in small volumes to 8 
maximize contact with the scaffold and incubated for 1 hour to allow attachment prior to the addition of 9 
media. For tubular scaffolds cannulation with a small gauge (< 30G) needle is necessary for seeding. 10 
This procedure is technically challenging and may require the assistance of a surgeon to avoid 11 
damaging the scaffold.  12 
The efficiency and quality of cell attachment following seeding (Fig. 9d-e and 10c-d) depends on clump 13 
size, cell number, seeding cell suspension volume and drying time for the scaffold. Single cells and low 14 
cell numbers are associated with reduced seeding efficiency, while large clumps may attach only 15 
partially. Importantly, parts of a clump which have not attached may remodel to form organoid-like 16 
structures connected to the scaffold or overlap with neighbouring clumps which have attached 17 
generating a pseudostratified epithelium. Consequently, the use of 30-50 cell clumps is crucial to 18 
achieve optimal seeding results.  19 
Low cell suspension volumes result in poor scaffold coverage and therefore suboptimal seeding, while 20 
cell viability may be reduced due to media evaporation during the incubation period. High volumes may 21 
lead to overflow and ‘spillage’ of the cell suspension from the scaffold to the plate resulting in a reduced 22 
cell-to-surface ratio and poor seeding efficiency. Consequently, the seeding volume must be optimized 23 
based on the scaffold surface as described in the procedure section. This is particularly important when 24 
seeding on the luminal surface of a tubular scaffold, where the cell suspension must be optimised for 25 
minimal volume and maximal density, to be contained within the tube lumen.   26 
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Reduced incubation time does not allow an adequate period for the cells to attach. Consequently, the 1 
addition of media at the end of the incubation phase results in washing the poorly attached cells off the 2 
scaffold. Prolonged incubation can result in scaffold drying and reduced cell viability.  3 
Importantly, the scaffold is rarely confluent following seeding. Indeed, in most cases only a proportion 4 
of the scaffold is covered with cells. However, these expand to generate a confluent layer within weeks. 5 
The time to confluency can be reduced by seeding higher number of cells or performing repeated 6 
rounds of seeding. Importantly, if an additional round of seeding is performed the scaffold should not 7 
be allowed to dry before the new cells are added to preserve the viability of the cells already attached.  8 
Bioengineered biliary tissue can be analysed through immunofluorescence or functional assays as 9 
previously described 4 and should show robust expression of key biliary markers such as cytokeratin 10 
19 and cytokeratin 7 (Fig. 11a, 11c and 11e) as well as key cholangiocyte functions such as GGT 11 
activity (Fig. 11b, 11d and 11f). Once confluent, the scaffolds can be transplanted in vivo or maintained 12 
in culture for several months. 13 
Scaffold specific considerations 14 
Pore size is an important consideration for PGA scaffolds. The scaffold pore size will determine the 15 
optimal cell clump size for seeding- scaffold with large pores would, in principle, allow deeper cell 16 
penetration, provided there is good interconnectivity between pores. However, constructs with larger 17 
pores are weaker, and seeding with large clumps is required to ensure the cells do not ‘fall through’ the 18 
spaces between fibres. Furthermore, preparation of the scaffolds for seeding includes treatment with 19 
ethanol and high concentration NaOH. It is crucial that at the point of seeding the scaffold is completely 20 
free of ethanol or NaOH remnants which could result in cell death and poor attachment.  21 
For collagen scaffolds, the quality of collagen plays a key role for the attachment and growth of cells. 22 
As collagen solutions are not 100% pure, testing of each new collagen batch for cell attachment, 23 
proliferation, expression of biliary markers and function is recommended.  24 
For the generation of tubular densified collagen scaffolds, assistance of an experienced engineer and 25 
access to engineering facilities, including a 3D printer, is essential. Furthermore, transplantation of 26 
bioengineered ducts into small animal models requires significant skill due to construct size and the 27 
procedure must be performed by an experienced surgeon.  28 
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Appropriate Controls 1 
Freshly isolated primary biliary tissue should be used as a positive control for the expression of biliary 2 
markers. For histology or immunofluorescence (IF) analyses, whole tissue can be frozen in OCT or 3 
fixed in 10% formalin and embedded in paraffin for sectioning. Cells can be isolated as described in 4 
step 2, sections A and D and dissociated to a single cell suspension for flow cytometry or resuspended 5 
in RNA lysis buffer for RNA extraction and quantitative PCR (QPCR), as described in steps 41, section 6 
C. Alternatively, RNA can be extracted from snap frozen tissue. While primary tissue represents the 7 
ideal control for CO function and marker expression, it is also possible to compare COs established 8 
cholangiocyte cell lines could be used as alternatives if access to primary tissue is not possible.  9 
Starting population considerations 10 
We have demonstrated that our protocol for cholangiocyte organoid derivation is reproducible with >70 11 
CO lines (Supplementary Table 1). Additionally, CO lines can be generated from very low numbers 12 
(<20,000) of viable primary cells (Supplementary Fig. 5). CO lines can be maintained in culture for >20 13 
passages or 6 months. COs represent primary cells rather than immortalized cell lines, therefore it is 14 
possible that a reduction in the growth potential of function of the line is observed after this time. The 15 
‘incubator life’ of each line varies and therefore the expansion potential, expression of biliary markers 16 
and function should be regularly tested after passage 20 to periodically validate the quality of the line.  17 
For the generation of bioengineered tissue, some variability in cell attachment and expansion potential 18 
following seeding and after transplantation is expected. Therefore, minor optimization may be required 19 




• Human bile duct, gall bladder and liver tissue samples or cholangiocytes from ERCP brushings. 24 
CAUTION: All human tissue samples must be collected with the appropriate ethical approval in place 25 
and with full informed consent. Donors should be tested to exclude HIV, hepatitis B and hepatitis C. 26 
15 
 
• William’s E basal medium, no phenol red (Invitrogen; cat. no. A12176-01) 1 
• Nicotinamide (Sigma Life science, cat. no. N0636-100G) 2 
• Sodium Bicarbonate (Sigma Life Science, cat. no. S6014-500G) 3 
• Sodium Pyruvate (Invitrogen, cat. no. 11360-070) 4 
• D- Glucose (Gibco, cat. no. 15023-021) 5 
• HEPES (Sigma, H0887-20ml) 6 
• ITS+ universal cell culture premix (20ml) (SLS, cat. no. 354352) 7 
• Dexamethasone (R&D Systems, cat. no. 1126/100) 8 
• L- Glutamine (Life Technologies, cat. no. 25030) 9 
• Penicillin-streptomycin (Life Technologies, cat. no. 15140122) 10 
• L-phospho-ascorbic acid (Sigma Life Sciences, cat. no. 49752-10G) 11 
• Matrigel (BD Biosciences, cat. no. 356237) 12 
• Cell recovery solution (SLS, cat. no. 354253) 13 
• Cell Banker 2 (Amsbio, cat. no. 11891) 14 
• Recombinant Human Epidermal Growth Factor (EGF) (R&D Systems, cat. no. 236-EG) 15 
• Recombinant Human DKK-1 protein (R&D Systems, cat. no. 5439-DK-01M/CF) 16 
• Recombinant Human Rspondin-1 (R&D Systems, 4645-RS) 17 
• Recombinant Human HGF (Peprotech, cat. no. 100-39) 18 
• Recombinant Human Forskolin (FSK) (Sigma Aldrich, cat. no. F6886-10MG) 19 
• Y27632 (Stratech Scientific, cat. no. S1049-SEL) 20 
• Liberase™ DL Research Grade (Sigma Aldrich, cat. no. 5466202001) 21 
• Deoxyribonuclease I from bovine pancreas (Sigma Aldrich, cat. no. D5025-150KU) 22 
• UW cold storage solution (Belzer; cat. no. BTLBUW-1000) 23 
• Dulbecco's PBS (DPBS; Life Technologies, cat. no. 14190) 24 
• Red Blood Cell Lysis Solution (10×) (MACS Miltenyi Biotech, cat. no. 130-094-183) 25 
• Bovine Serum Albumin (Sigma Life Sciences, cat. no. A3059) 26 
• PolyGlycolic Acid BIOFELT scaffold (1 mm thickness, 50 mg/cm3 PGA density) (Biomedical 27 
structures LLC, custom order- enquire with the manufacturer)  28 
• CD326 (EpCAM) MicroBeads, human (MACS Miltenyi Biotech, cat. no. 130-061-101) 29 
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• FcR Blocking Reagent (MACS Miltenyi Biotech, cat. no. 130-059-90) 1 
• MACS BSA Stock Solution (MACS Miltenyi Biotech, cat. no. 130-091-376)  2 
• AutoMACS™ Rinsing Solution (MACS Miltenyi Biotech, cat. no.  130-091-222) 3 
• AutoMACS® running buffer (MACS Miltenyi Biotech, cat. no. 130-091-221) 4 
• AutoMACS® pro washing solution (MACS Miltenyi Biotech, cat. no. 130-092-987) 5 
• Collagen I, High concentration rat tail collagen solution, 100 mg (Scientific Laboratory Supplies, 6 
354249)   7 
• 10x M199 (Sigma, cat. no. M0650) 8 
• 1M Sodium Hydroxide (Sigma, cat. no. 2770) 9 
CAUTION: Sodium hydroxide can cause inflammation, irritation or corrosion upon contact with 10 
skin, eyes or when ingested or inhaled. It should be handled while wearing appropriate safety 11 
equipment 12 
• DI water 13 
• Water for embryo transfer (Sigma, cat. no. W1503) 14 
• Trigene (Distel concentrate; Starlab, cat. no. TM309) 15 
• Absolute ethanol (Fisher Scientific, cat. no. 10041814) 16 
• Trypan Blue solution (Thermo Fisher Scientific, cat. no. 15250061) 17 
CAUTION: Trypan Blue is a potential carcinogen and can potentially cause damage to fertility 18 
• Donkey serum (AbD Serotec, cat. no. c06sb) 19 
• Triton-X100 solution (Sigma, cat. no. X100-500ML) 20 
• Paraformaldehyde 16% (wt/vol) (PFA; Alfa Aesar, cat. no. 30525-89-4) 21 
CAUTION: Paraformaldehyde contains formaldehyde, which is carcinogenic. 22 
Paraformaldehyde can cause tissue damage if inhaled, ingested or exposed to skin and should 23 
be handled using appropriate safety measures  24 
• Cytokeratin 7 antibody (Abcam, cat. no. ab68459; Table 1) 25 
• Cytokeratin 19 antibody (Abcam, cat. no. ab7754; Table 1) 26 
• Goat anti-human Sox9 (R&D Systems, cat. no. AF3075; Table 1) 27 
• Rabbit anti-human albumin (Abcam, cat. no. ab137885; Table 1) 28 
• Mouse anti-human GGT-1 (Abcam, cat. no. ab55138; Table 1) 29 
• Donkey anti-mouse Alexa Fluor 488 (Life Technologies, cat. no. A2102; Table 1) 30 
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• Donkey anti-rabbit Alexa Fluor 568 (Life Technologies, cat. no. A10042; Table 1) 1 
• Donkey anti-goat Alexa Fluor 488 (Life Technologies, cat. no. A21447; Table 1) 2 
EQUIPMENT 3 
• Plate heater (TAP Biosystem, cat. no. 016-0R10) 4 
• Inverted microscope (Olympus, cat. no. CKX41) 5 
• 100-mm TC-Treated Culture Dish (Corning, cat. no. 430167) 6 
• Costar 24-Well Clear TC-Treated Multiple-Well Plates (Corning, cat. no. 3526) 7 
• Surgical Scalpel Blade No.22 (sterile) (Swann Morton Ltd, cat. no. 0508) 8 
• Dumont #5 - Fine Forceps (F.S.T., cat. no. 11254-20) 9 
• 15 ml and 50 ml Centrifuge tubes (Corning, cat. nos. 430791 and 430291) 10 
• 500-ml Vacuum Filter/Storage Bottle System, 0.22-μm pore (Corning, cat. no. 431097) 11 
• CO2 incubator (Sanyo, cat. no. MCO-18AC) 12 
• Centrifuge (Eppendorf, cat. no. 5804) 13 
• Orbital shaking incubator (New Brunswick Scientific, cat. no. M1299-0082) 14 
• Disposable serological pipettes (5, 10 and 25 ml) (Corning, cat. nos. 4487, 4488 and 4489) 15 
• Graduated filter tips (1000, 200, 20 and 10 μl) (Starlab, cat. nos. S1122-1830, S1120-8810, 16 
S1120-1810, S1120-3810) 17 
• Cryotube vials (2 ml) (Thermo Scientific, cat. no. 368632) 18 
• AutoMACS® Pro Separator (MACS Miltenyi Biotech, cat. no. 130-092-545) 19 
• 40 μm cell strainers (Corning, cat. no. 352340) 20 
• Countess™ II Automated Cell Counter (Thermo Fischer Scientific, cat. no. AMQAX1000) 21 
• CountessTM cell counting chamber slides (Thermo Fischer Scientific, cat. no. C10283) 22 
• Insulin syringes, 1 ml (VWR International, cat. no. 613-4892) 23 
• Syringes, 20 ml (Fisher Scientific, cat. no. 15829152) 24 
• Needles, 18G, 23G (Camlab, cat. no. 305180, 300700) 25 
• Stainless steel fine tweezers (Onecall, cat. no. 1779183) 26 
• Dissecting scissors, straight (Fisher Scientific, cat. no. 15207266) 27 
• Precision wipes, Kimtech (Fisher Scientific, cat. no. 12660543) 28 
• Self-seal sterilisation pouches (Fisher Scientific, cat. no. 15428782) 29 
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• 0.2 µm syringe filters (Fisher Scientific, cat. no. 10268401) 1 
• 6 well plates (Fisher Scientific, cat. no. 10396482) 2 
• Autoclave tape (Greiner Bio-One, cat. no. TAP02) 3 
• Micro-spatula, 21 mm length (VWR International, cat. no. 231-0446) 4 
• Specimen tubes, flat bottom, 10 mm (Samco, cat. no. G05017) 5 
• Nylon membrane, 10 μm pore size, hydrophilic (Millipore, cat. no. NY1002500 ) 6 
• 25 μl Model 1702 Hamilton syringe (Hamilton, cat. no. 80265) 7 
• 34 gauge small hub removable needle (Hamilton, cat. no. 207434) 8 
Critical: While the exact make and model of syringe and removable needle can vary according to 9 
the researcher’s preference, it is essential that small volume syringes and removable needles with 10 
no dead space are used for seeding the tubular scaffolds (step 40, section B), due to the very small 11 
(25 μl) volumes needed for seeding. 12 
 13 
REAGENT SET UP 14 
• Human biliary and liver tissue Primary tissue can be obtained from surgically excised 15 
gallbladder or bile duct tissue, ERCP brushings or liver biopsies. Once collected, tissue should 16 
be stored immediately at 4°C in Williams E+ media with 50 ng/ml of EGF and 10 μM of Y27632 17 
or in University of Wisconsin (UW) cold storage solution. 18 
 CAUTION: Leaving primary tissue longer than 8 hours before processing will negatively affect the 19 
viability of the isolated cells 20 
• Nicotinamide 0.4 M stock solution Dissolve 24.4 g of nicotinamide powder in 500 ml of 21 
embryo transfer water. 22 
CRITICAL: Sterilize nicotinamide stock solution using a vacuum filter/storage bottle system. 23 
Mix it well before filtration. Store the solution at 4 °C for up to 3 months. 24 
 25 
• Sodium bicarbonate 1 M stock solution preparation Dissolve 42 g of sodium bicarbonate 26 
powder in 500 ml of embryo transfer water. 27 
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CRITICAL: Sterilize sodium bicarbonate stock solution using a vacuum filter/storage bottle 1 
system. Mix it well before filtration. Store the solution at 4 °C for up to 3 months. 2 
 3 
• Ascorbic acid trisodium salt 100 mM stock solution preparation Dissolve 16.1 g of ascorbic 4 
acid trisodium salt powder in 500 ml of embryo transfer water. 5 
CRITICAL: Sterilize ascorbic acid trisodium salt stock solution using a vacuum filter/storage 6 
bottle system. Mix the solution well before filtration. Store it at 4 °C for up to 3 months. Protect 7 
it from light. 8 
 9 
• D-Glucose 1 M stock solution preparation Dissolve 90.1 g of D-glucose powder in 500 ml of 10 
embryo transfer water. Warm the mixture to 50 °C to facilitate dissolution. 11 
CRITICAL: Sterilize D-glucose stock solution using a vacuum filter/storage bottle system. Mix 12 
the solution well before filtration. Store it at 4 °C for up to 3 months. 13 
 14 
• Dexamethasone 10 mM stock solution Dissolve 100 mg of dexamethasone in 25.4797 ml of 15 
DMSO. Prepare 50- to 100-μl aliquots. Store them at −80 °C for up to 12 months. 16 
 17 
• Supplemented William's E medium (Willliam’s E+) Combine 443 ml of William's E medium 18 
with 12.5 ml of nicotinamide stock solution, 8.5 ml of sodium bicarbonate stock solution, 1 ml 19 
of ascorbic acid trisodium salt stock solution, 7 ml of glucose stock solution, 3.15 ml of sodium 20 
pyruvate, 10 ml of HEPES solution, 5 ml of ITS+ premix, 5 μl of dexamethasone (R&D 21 
Systems), 5.3 ml of glutamine and 5 ml of pen/strep. 22 
CRITICAL: Sterilize William’s E+ medium using a vacuum filter/storage bottle system. Mix the 23 
medium well before filtration. Store it at 4 °C for up to 1 month. Warm it to 37 °C before use. 24 
 25 
• Sodium bicarbonate 7.5 % (wt/vol) stock solution Dissolve 3.75 g of sodium bicarbonate 26 
powder in 46.25 ml of deionised water.  27 
CRITICAL: Sterilize sodium bicarbonate stock solution using a 50 ml syringe and 0.2 μm 28 




• 70% (wt/vol) ethanol. Combine 700 ml of absolute ethanol and 300 ml deionised water. 1 
 2 
• Matrigel preparation. 10 ml Matrigel vials should be thawed slowly in a refrigerator placed at 3 
4 °C overnight. Thawed Matrigel should be mixed well and then divided into 1 ml aliquots. 4 
Aliquotting of Matrigel should always be performed in a tissue culture hood to avoid bacterial 5 
contamination. Matrigel should be kept constantly on ice to avoid solidification. All equipment 6 
coming into contact with Matrigel should be precooled to 4 °C. This includes pipette tips and 7 
media for diluting Matrigel. Tubes for aliquotting should be kept on ice. Store Matrigel aliquots 8 
at −20 °C or −80 °C for up to 3 months. 9 
CRITICAL: Each aliquot should undergo a maximum of two freeze–thaw cycles. This can be 10 
achieved by adjusting aliquot volumes accordingly. 11 
 12 
• Preparation of a 3X supplemented William’s E+ solution. William’s E+ media is 13 
supplemented with 1.5 μg/ml RSPO, 300  ng/ml DKK, 150 ng/ml EGF and 3 μM Y27632 (3X 14 
the typical concentration of all Supplementary cytokines).  15 
 16 
COs are cultured in 3D conditions, suspended in 50 μl droplets composed of a 66.7% (vol/vol) 17 
Matrigel and 33.3% (vol/vol) 3X supplemented William’s E+ solution, which form a dome after 18 
plating (Fig. 4b, Image 6A(i)). Prior to plating, a master mix is prepared with a volume 19 
corresponding to the number of droplets that will be plated as described in steps 3-10. 20 
Importantly, for generating this master mix COs or primary cholangiocytes are first resuspended 21 
in the 3X supplemented William’s E+ solution (step 3) and Matrigel is subsequently added (step 22 
5). To calculate the volume of supplemented William’s E+ needed for resuspension of the CO 23 
pellet, the following formula can be used:  24 
 25 
Volume of supplemented William’s E+ media= [(number of CO wells) x 50 μl]/3 26 
 27 
CRITICAL: As the volume of media needed to resuspend the CO pellet will typically be very 28 
small, it is advisable to instead prepare a larger volume of 3X concentrated William’s E+ 29 
solution. This can then be diluted to 1X and added to the wells after plating as their plating 30 
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medium. This volume corresponds to 1/3 the total number of wells to be plated (e.g. if plating 1 
12 wells, prepare 4 ml of 3X William’s E+ solution) assuming 1ml of media / well is used. A 2 
small aliquot of the resulting 3X solution can then be used to resuspend the pellet and the 3 
remaining solution can be diluted to 1X with William’s E+ devoid of additional cytokines and 4 
used as plating medium.  5 
E.g. If plating 12 wells, resuspend the pellet in 200 μl of 3X supplemented William’s E+ 6 
solution, taken from the initial 4 ml of 3X supplemented William’s E+ solution. After CO 7 
plating (steps 3-10), add 8 ml of non-supplemented William’s E+ media to the 4 ml of 8 
supplemented William’s E+ solution to make a 1X supplemented William’s E+ solution 9 
 10 
Preparation of a 66.7% Matrigel (vol/vol) solution To obtain the volume of Matrigel 11 
needed when plating, multiply the volume of 3X supplemented William’s E+ solution by 12 
two. E.g. if plating 12 wells, 200 μl of supplemented William’s E+ solution should be added 13 
to the pellet followed by 400 μl of Matrigel. 14 
CRITICAL: The 3X supplemented William’s E+ solution should be precooled to 4 °C 15 
 16 
CRITICAL: Both Matrigel and the 3X supplemented William’s E+ solution should be kept on 17 
ice for the duration of the procedure to avoid Matrigel solidification 18 
 19 
• Liberase preparation Reconstitute the lyophilised liberase enzyme with 10 ml of sterile 20 
injection-quality water, as per the manufacturer’s instructions, to obtain a stock solution.  21 
CRITICAL: Aliquot the reconstituted liberase stock solution into 1 ml aliquots to avoid repeated 22 
freeze-thaw cycles and store at -15 to -25 °C. Reconstitution and aliquotting should take place 23 
in a tissue culture hood to avoid contamination. 24 
 25 
• DNase I preparation Reconstitute the lyophilised DNase I to a 4 mg/ml stock solution using 26 
sterile PBS.  27 
CRITICAL: Aliquot the reconstituted DNase I stock solution into 100 μl aliquots to avoid 28 
repeated freeze-thaw cycles and store at -80 °C. Reconstitution and aliquotting should take 29 




• PBS 1% BSA (wt/vol) preparation Weigh out 5 g of BSA powder and dissolve in 500 ml of 2 
PBS to obtain a 1% solution.  3 
CRITICAL: Sterilize PBS 1% BSA solution using a vacuum filter/storage bottle system. Mix the 4 
solution well before filtration. Aliquot in 50 ml centrifuge tubes and store at -20 °C to avoid 5 
contamination. 6 
 7 
• MACS buffer preparation Prepare a 1 in 20 dilution of MACS BSA stock solution in 8 
AutoMACS™ Rinsing Solution 9 
CRITICAL: MACS buffer should be freshly prepared at point of use and should be kept at 4 °C. 10 
Buffer preparation should take place in a tissue culture hood to avoid contamination 11 
 12 
• Preparation of a 0.1% Triton X-100 solution Add 50 μl of Triton X-100 to 50 ml of PBS in a 13 
50 ml centrifuge tube. Gently shake the tube by inversion until the Triton X-100 is fully dissolved 14 
 15 
EQUIPMENT SET UP 16 
Plate heater setup  17 
• Clean the plate heater with trigene and 70% (vol/vol) ethanol and place it in a tissue culture 18 
hood. Set the temperature to 37 °C and place a 24-well plate on the heating surface. 19 
CRITICAL: Allow a minimum of 30 min for the plate to warm up, before plating Matrigel with cells. If you 20 
are using multiple plates, these can be prewarmed in an incubator for a minimum of 30 min, with each 21 
plate placed on the plate heater immediately before plating. 22 
AUTOMACS pro separator set up 23 
• Run column exchange before use. Check that the columns are secured and there are no leaks 24 
anywhere in the system. Check that there is sufficient running buffer, washing solution and 70% 25 
(vol/vol) ethanol and that the waste bottle is not too full. Run an additional “Qrinse” before 26 
starting cell sorting. This can be done while the cells are incubating with the MACS beads to 27 
23 
 
save time. To shut down the machine after EpCAM+ sorting, select the “sleep” programme. 1 
Turn off the machine once the “sleep” programme has finished 2 
Fabrication and assembly of densification chamber for densified collagen tubes. 3 
 Critical step: The densification chamber, used to form the densified collagen tubes, requires 4 
fabrication and assembly ahead of the collagen gel preparation. This involves 3D printing the base and 5 
funnel pieces, mounting a rigid metal wire in the base, and fixing paper towels between the base and 6 
funnel. This procedure requires access to basic engineering facilities. 7 
I. Design chamber geometry in computer-aided design (CAD) package (e.g. Autodesk 8 
Inventor). See Supplementary Software 1 and 2 for reference. 9 
II. Export as .stl file and prepare file for 3D printing using 3D printer software (e.g. Doraware). 10 
III. 3D print chamber model using poly-lactic acid (PLA) filament and assemble components 11 
shown in Fig. 8a, Image 1. 12 
IV. Mount straight rigid wire in hole of base piece of chamber by supergluing it into place (Fig. 8a, 13 
Image 2).  14 
Critical step: Let superglue cure before continuing (1 hour). 15 
V. Fold 2 sheets of absorbent precision wipe paper towels four times and using scissors, cut to 16 
size of base plate. Autoclave these paper towels in an autoclave pouch.  17 
Critical step: Let towels fully dry before continuing. 18 
VI. Sterilize base plate and funnel piece by immersion in 70% (vol/vol) ethanol. 19 
VII. Place 3D printed components under a sterile biological cabinet until dry.  20 
VIII. Autoclave 4x M4 screws and nuts. 21 
IX. Using a sterile 23G needle, punch a hole through the centre of the sheets and feed the 22 
mounted metallic wire through the needle (Fig. 8a, Image 3). 23 
X. Pull out 23G needle and push down paper towels. 24 
XI. Feed metallic wire through funnel piece (Fig. 8a, Image 4) and fix funnel piece to base piece 25 
using 4x M4 screws and nuts (Fig. 8a, Image 5). 26 
XII. Tighten using screwdriver. Chamber is now ready for densification process. 27 
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Critical Step: Screws must be tight in order to prevent leaking of water to the towels prior to a collagen 1 
gel forming. 2 
Critical Step: The top of the metallic wire must not extrude above the top of the funnel. This is a 3 
necessary condition for successful collagen densification for tube formation. 4 
 5 
PROCEDURE 6 
Derivation of cholangiocyte organoids from primary human tissue 7 
1. Primary tissue can be obtained from surgically excised gallbladder or bile duct tissue, ERCP 8 
brushings or liver biopsies (Fig. 1b). Once collected, tissue should be stored immediately as 9 
described in “reagent setup”.  10 
Pause point: Tissue can be kept in media/cold storage solution for up to 8 hours although for optimal 11 
viability, tissue should be processed as soon as possible after collection. Guidance on the maximum 12 
length of storage before processing for each tissue type is shown in Supplementary Fig. 1. 13 
CAUTION: Dissection of tissue should take place in a category 2 cell culture hood under aseptic 14 
conditions 15 
2. For derivation of COs from excised bile ducts or gall bladders, see section A. For derivation of 16 
COs from ERCP brushings, see section B. For derivation of COs from liver tissue, see section 17 
C and for derivation of COs from an EpCAM+ sorted single cell suspension, see section D. 18 
Step 2, Section A: Derivation of extrahepatic cholangiocyte organoids from deceased organ 19 
donors 20 
Timing: 1-2 hours (including plating) 21 
Critical step: All equipment used should be sterile and all work must be done under aseptic conditions 22 
in a category 2 tissue culture hood.  23 
I. Transfer the tissue from the storage container onto an empty 10 cm plate. 24 
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II. Using a scalpel and forceps, make a longitudinal incision along the length of the excised bile 1 
duct or from the fundus to the neck of the excised gallbladder. (Fig. 2b, Images 1A(ii) and 2B(ii)) 2 
to expose the lumen.  3 
This step should result in a flat sheet of biliary tissue with the biliary epithelium on the luminal 4 
surface, usually pigmented yellow by bile and an ‘exterior’ surface corresponding to the outer 5 
wall of the bile duct or gallbladder.  6 
CAUTION:  Ensure the luminal surface is facing upwards to avoid loss of cholangiocytes 7 
 8 
III. Wash the tissue by transferring in a 50 ml centrifuge tubes containing PBS to remove excess 9 
bile (Fig. 2b and c, Image 2). Repeat twice using a fresh tube each time [Troubleshooting]  10 
Critical step: PBS washes must be performed cautiously to prevent detachment of the biliary 11 
epithelial layer. This is particularly important if the bile duct or gallbladder tissue has been kept on 12 
ice for <2-4 hours after surgical excision 13 
IV. Transfer the tissue to an empty plate 14 
V. Add Williams’ E+ media to the plate until the tissue is fully submerged in media. It is not 15 
necessary to supplement the media with additional cytokines. 16 
CAUTION: The tissue must be submerged in media quickly to prevent it from drying 17 
VI. Gently scrape the luminal surface of the tissue with a scalpel to release the cholangiocytes into 18 
the media (Fig. 2b and c, Image 3) 19 
Critical step: Examine the cell suspension under the microscope after scraping the tissue and before 20 
collecting the cells into a centrifuge tube to ensure the mechanical dissociation has been successful. 21 
The epithelial cells should be released from the tissue as small clumps and should display columnar 22 
morphology (Fig. 2b and c, Image 9). 23 
VII. Collect the media and cells into a 50 ml centrifuge tube using a 10 ml pipette 24 
VIII. Wash the tissue again by adding approximately 10 ml of fresh media directly on the luminal 25 
surface of the tissue in the plate with a 10 ml pipette 26 
IX. Repeat the process of scraping and washing until the entire epithelial layer is collected. By the 27 
end of this stage, the luminal side of the biliary tissue will appear smooth, losing the 28 
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characteristic velvet-like appearance of the biliary epithelium (Fig. 2b and c, Images 1A(iii) and 1 
1B(iii)).  2 
Critical step: Scrape cautiously to avoid releasing fibrous tissue and debris into the cell suspension 3 
[Troubleshooting] 4 
X. Centrifuge the cells at 444 g for 4 minutes at room temperature (23 °C) 5 
XI. Aspirate the supernatant 6 
XII. Resuspend the pellet in 10 ml of WE+ media (regardless of pellet size) to wash the cells.  7 
If there is bile or debris remaining in the suspension, repeat this wash step. 8 
Critical step: Remove large pieces of debris and fibrous tissue using a p1000 pipette as these may 9 
not be easily removed by washing [Troubleshooting] 10 
XIII. Centrifuge the cells at 444 g for 4 minutes at room temperature 11 
XIV. Optional step: Red cell lysis to avoid erythrocyte contamination 12 
XV. Optional step: Resuspend in 10 ml of ice cold red cell lysis buffer  13 
XVI. Optional step: Incubate the cell suspension on ice for up to ten minutes.  14 
XVII. Optional step: Wash twice in William’s E+ media as described in steps XI – XII before continuing 15 
with step XXI 16 
XVIII. Aspirate the supernatant 17 
XIX. Wash the pellet in William’s E media.  18 
XX. Plate the cells as described in steps 5-14 [Troubleshooting] 19 
Critical step: typical morphology for COs plated from GB or BD tissue after one week and >20 weeks 20 
after plating is displayed in Fig. 2d Image 1 and 2d Image 2 respectively. COs should begin to form 21 
approximately 3 days after plating and debris should disappear from the CO culture after the first two 22 
passages 23 
 24 
Step 2, Section B: Derivation of extrahepatic cholangiocyte organoids through Endoscopic 25 
retrograde cholangiopancreatography (ERCP) brushings 26 
Timing: 30 minutes 27 
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I. Prepare a 50 ml centrifuge tube of William’s E+ media with 50 ng/ml of EGF and 10 μM of 1 
Y27632. Provide this tube to the clinicians before the start of the ERCP procedure 2 
II. Following brushing, wash the ERCP brush in the tube of media to dislodge the collected cells 3 
(Fig. 3a, panel 2) 4 
III. Transport the centrifuge tube at 4 °C to a category 2 tissue culture hood under aseptic 5 
conditions 6 
IV. Centrifuge the 50 ml tube at 444 g for 4 minutes at room temperature 7 
V. Plate the resulting pellet of cells as described in the “plating of cholangiocyte organoids” section 8 
below (steps 3-10) [Troubleshooting] 9 
Critical step: typical morphology of COs derived from ERCP brushings immediately after plating, 24 10 
hours after plating and one week after plating are displayed in Fig. 3b Image 5, 3c Image 1 and 3c 11 
Image 2 respectively. Organoids should begin to form within 24 hours of plating and debris should 12 
disappear from the organoid culture after the first two passages. 13 
 14 
Step 2, Section C: Derivation of intrahepatic cholangiocyte organoids from liver tissue 15 
Timings: 30-40 minutes (including plating) 16 
I. Place a liver biopsy core into a well of a 6 well tissue culture plate. Alternatively, place a small 17 
piece of liver tissue (approximately 1 cm3) on a sterile 10 cm tissue culture dish and cut into 18 
small pieces (approximately 3-4 mm3) before transferring into a well of a 6 well plate for further 19 
dissection 20 
II. Using a scalpel, carefully dissect the tissue into as small pieces as possible, approximately <1 21 
mm3  (Fig. 4b and c, Image 1) [Troubleshooting] 22 
Critical step: Care should be taken to ensure the tissue is cut as small as possible so it can fit into a 23 
p1000 pipette tip (Fig. 4b and c, Image 2). Tissue dissection should be done as quickly as possible to 24 
prevent the tissue from drying out. 25 
III. Add 1 ml of William’s E+ media with 50 ng/ml EGF, 10 μM (1 μl/ml) Y27632 to the dissected 26 
liver tissue 27 
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IV. Transfer the dissected tissue and media into a 15 ml centrifuge tube using a p1000 pipette (Fig. 1 
4b and c, Image 3) and centrifuge at 300 g for 2 minutes at room temperature (Fig. 4b and c, 2 
Image 4) 3 
V. Carefully aspirate the supernatant 4 
VI. Wash the pellet in Williams E+ media  5 
VII. Centrifuge at 300 g for 2 minutes at room temperature 6 
VIII. Plate the dissected tissue pieces following the instructions in the “plating of cholangiocyte 7 
organoids” section below (steps 3-10) (Fig. 4b and c, Image 6(i)) [Troubleshooting] 8 
Critical step: Typical morphology for COs plated from diced liver tissue < one week after plating and 9 
>20 weeks after plating is displayed in Fig. 4d Image 1 and 4d Image 2 respectively.  10 
 11 
Step 2, Section D: Derivation of intrahepatic cholangiocyte organoids through EpCAM+ MACS 12 
sorting 13 
Timing: 2-3 hours 14 
Critical step: the liberase and DNase I solutions should be pre-warmed to 37 °C before starting the 15 
isolation process 16 
I. Place a liver biopsy core into a well of a 6 well tissue culture plate. Alternatively, place a small 17 
piece of liver tissue (approximately 1 cm3) on a sterile 10 cm tissue culture dish and cut into 18 
small pieces (approximately 3-4 mm3) before transferring into a well of a 6 well plate for further 19 
dissection 20 
II. Using a sterile scalpel, dissect the tissue into very small pieces < 1 mm3 (Fig. 4b and c, Image 21 
2) 22 
III. Add 1.5 ml of pre-warmed liberase digestion solution (0.5 U) with 4 mg/ml of DNase I 23 
(Supplementary Fig. 2b, Image 3) 24 
Critical step: DNase I must be added during the dissociation to prevent the cells from forming clumps.  25 
IV. Place the plate on a heated orbital shaker at 170 rpm and 37 °C for 30 minutes. Ensure the 26 
plate is secured to the orbital shaker. 27 
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V. Every ten minutes, remove the tube from the rocker and gently pipette up and down with a 1 
p1000 pipette. 2 
Critical step: Examine the cells under the microscope at these ten minute intervals to check the progress 3 
of the dissociation. The dissociation will be finished once all the tissue has been dissociated to a single-4 
cell suspension, with only the collagen scaffold of the tissue remaining (Supplementary Fig. 2b, Image 5 
4). [Troubleshooting] 6 
VI. After 30 minutes, stop the reaction by adding an equivalent volume of cold PBS 1% BSA 7 
(wt/vol).  8 
VII. Filter through a 40 μm filter into a 15 ml centrifuge tube [Troubleshooting] 9 
Critical step: filter gently and do not force any material through the filter as this will reduce viability and 10 
result in fibrous material in the final cell suspension 11 
VIII. Centrifuge at 444 g for 4 minutes at room temperature 12 
IX. Aspirate the supernatant using a p1000 pipette 13 
X. Resuspend the pellet in 10 ml of red cell lysis buffer with 4 mg/ml of DNase I and 10 μM of 14 
Y27632 15 
Critical step: Aspiration of the supernatant should not be done using a vacuum pump aspirator from this 16 
stage onwards as this presents a risk of losing the pellet 17 
XI. Incubate the cells on ice in red cell lysis buffer for up to ten minutes.  18 
XII. Add an equivalent volume of PBS 1% BSA (wt/vol) to the red cell lysis buffer and centrifuge at 19 
444g for 4 minutes at room temperature 20 
XIII. Aspirate the supernatant using a p1000 pipette and resuspend in 1 ml of cold PBS 1% BSA 21 
(wt/vol) with 4 mg/ml of DNase I and 10 μM of Y27632.  22 
XIV. Repeat this wash step one more time to ensure the complete removal of the red cell lysis buffer, 23 
and resuspend the pellet once more in in 1ml of cold PBS 1% BSA (wt/vol) with 4 mg/ml of 24 
DNase I  and 10 μM of Y27632 25 
XV. Take a 10 μl aliquot of the cell suspension and mix with an equivalent volume of Trypan Blue. 26 
Count the cells using a haemocytometer or an automated cell counter. [Troubleshooting] 27 
XVI. Centrifuge the pellet at 444 g for 4 minutes at room temperature.  28 
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XVII. Resuspend the pellet in the appropriate volume of MACS buffer, FcR blocking reagent and 1 
CD326 (EpCAM) MicroBeads according to the manufacturer’s instructions  2 
Critical step: Use the cell count obtained in step XV to determine the appropriate volume of each 3 
reagent to add for the number of cells according to the manufacturer’s instructions (300 μl MACS 4 
buffer, 100 μl FcR blocking reagent and 100 μl CD326 (EpCAM) MicroBeads for every 5 x 107 total 5 
cells) 6 
XVIII. Incubate the cells for 30 minutes at 4 °C 7 
XIX. While the cells are incubating, prepare the AutoMACS® Pro Separator for cell sorting. See 8 
“AUTOMACS® pro separator set up” in “Equipment Setup” for instructions. 9 
XX. Wash the cells with 5 ml of PBS 1% BSA (wt/vol)  10 
XXI. Centrifuge at 300 g for 10 minutes at room temperature 11 
XXII. Aspirate the supernatant and resuspend in 5 ml of PBS 1% BSA (wt/vol) with 4 mg/ml of DNase 12 
I and 10 μM of Y27632 13 
XXIII. Filter the sample through a 40 μm filter immediately before sorting (Supplementary Fig. 2b, 14 
Image 6) 15 
XXIV. Run the sample through the AutoMACS® Pro Separator on a “POSSELD” programme. This 16 
will select for the EpCAM+ fraction. Collect the EpCAM+ fraction in a 15 ml centrifuge tube. 17 
[Troubleshooting] 18 
Critical step: Ensure this takes place under aseptic conditions- the AutoMACS® Pro Separator should 19 
be in a tissue culture hood and all buffers and running solutions should be kept sterile.  20 
Critical step: The MACS centrifuge tube rack should be pre-cooled in the fridge for at least an hour 21 
before use 22 
XXV. Top up the 15 ml centrifuge tube with PBS 1% BSA (wt/vol) 23 
XXVI. Centrifuge at 444 g for 4 minutes at room temperature  24 
XXVII. Plate the cell suspension following the instructions in the “plating of cholangiocyte organoids” 25 
section (steps 3-10) below. [Troubleshooting] 26 
XXVIII. Critical step: Typical morphology for COs plated from EpCAM+ sorted liver tissue < one week 27 
after plating is displayed in (Supplementary Fig. 2c). Organoids will grow from single cells over 28 
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the course of 5-15 days after plating. After the first passage, EpCAM+ sorted organoids will 1 
display typical CO morphology, as demonstrated in Supplementary Fig. 4a, Image 5).  2 
 3 
Plating of primary cholangiocytes in organoid format 4 
Timing: 10-40 minutes 5 
Critical step: Pre-heat an adequate number of 24-well tissue culture plates at 37 °C for at least one hour 6 
prior to use (pre-heating overnight is preferable) 7 
Critical step: Thaw Matrigel on ice for two hours to overnight prior to starting the isolation procedure. 8 
Matrigel will solidify at room temperature and so should always be kept on ice when in use. It is important 9 
to work quickly to prevent the Matrigel solidifying during the plating procedure. 10 
Critical step: COs should be plated in 3D Matrigel domes composed of a 2:1 ratio (33.3% to 66.7% 11 
vol/vol solution) of Matrigel and William’s E+ media. The CO pellet must first be resuspended in a 3X 12 
supplemented William’s E+ solution before the separate addition of Matrigel. See “preparation of a 3X 13 
supplemented William’s E+ solution” in Reagent Setup for instructions on how to calculate the volumes 14 
of 3X William’s E+ and Matrigel required to prepare this solution.   15 
3. Resuspend the CO pellet in a volume of the 3X supplemented William’s E+ solution appropriate 16 
for the number of wells being plated. E.g. if plating 9 wells, resuspend in 150 μl of WE+ media 17 
with 1.5 µg/ml R-spondin, 150 ng/ml EGF, 30 μM (3 μl/ml) Y27632 and 300 ng/ml DKK-1. 18 
Critical step: Y27632 should always be freshly added at this stage and kept in the culture media for 48 19 
hours to ensure maximal survival of the cholangiocyte cells 20 
4. Mix the Matrigel stock thoroughly with a p1000 pipette.  21 
Critical step: Matrigel should be kept on ice throughout the entire procedure and must be mixed with 22 
care to avoid bubbles 23 
5. Add Matrigel to the cell suspension in a 2:1 ratio (66.7% vol/vol) and mix well. See “preparation 24 
of a 66.7% Matrigel (vol/vol) solution” for instructions on how to calculate the amount of Matrigel 25 
required.  26 
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6. Plate the organoids in 50 µl Matrigel/media domes using a p1000 pipette, each in a well of a 1 
24 well plate. To plate the dome, hold the tip of the p1000 pipette very close to the surface of 2 
the well, in the centre, and slowly start pipetting. Move the pipette upwards as the droplet forms. 3 
[Troubleshooting] 4 
Critical step: Do not go down to the second stop of the pipette as this will form bubbles in the Matrigel 5 
dome.  6 
Critical step: Mix thoroughly before plating each dome 7 
7. Allow the Matrigel to solidify for 1-2 minutes in the plate heater. Gently tilt the plate to test that 8 
the Matrigel has solidified.  9 
8. Invert the plate and keep in the 37 °C incubator for 30 minutes. This step should be omitted 10 
when plating dissected liver tissue (Section C) or EpCAM+ sorted single cells (Section D) 11 
[Troubleshooting] 12 
Critical step: Without the plate inversion step, cell clumps are likely to migrate to the bottom of the well 13 
and attach to the plate. If this happens, the cells will not be able to form organoids. 14 
9. Make up the 3X William’s E+ media solution to a final concentration of 500 ng/ml Rspondin, 50 15 
ng/ml EGF, 10 μM (1 μl/ml) Y27632 and 100 ng/ml DKK-1 (+/- 50 ng/ml HGF) by following the 16 
formula below 17 
 Final volume of media = initial volume of media prepared in step 5 + [initial volume of media prepared in step 5 x 2] 18 
E.g. If 1 ml of media was initially prepared with 1.5 μg/ml Rspondin, 150 ng/ml EGF, 30 μM (3 μl/ml) 19 
Y27632 and 300 ng/ml DKK-1 (+/- 50 ng/ml HGF and 6 μM FSK), add a further 2 ml of William’s 20 
E+ media without cytokines, for a total of 3 ml of media with 500 ng/ml Rspondin, 50 ng/ml EGF, 21 
10 μM (1 μl/ml) Y27632 and 100 ng/ml DKK-1 (+/- 50 ng/ml HGF and 2 μM FSK) 22 
10. Add 1 ml of this supplemented media per organoid well using a 5 ml or 10 ml pipette. 23 
Critical step: Add the media slowly to the side of each well to avoid disrupting the Matrigel domes 24 
Critical step: When plating from primary cells, organoids from the common bile duct and gallbladder 25 
should begin to form within two days of plating and should be ready for the first passage within 5-7 26 
days of initial plating (Fig. 2d, Image 2 and Fig. 3c, Image 2). Organoids from liver biopsies or excised 27 
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liver tissue should take about 5-10 days to develop (Fig. 4d, Image 2) and should be passaged when 1 
the plate is approaching 80% confluency [Troubleshooting].  2 
Critical step: CO lines should always express the biliary markers CK19, CK7, Sox9 and GGT (Fig. 6a 3 
and 6b) and display ALP and GGT activity (Fig. 6c and 6d, respectively). Established CO lines should 4 
comprise a <99% pure population of CK19+/CK7+ cells (Fig. 6e). After approximately passage 2, CO 5 
lines derived from different tissues of origin or through different derivation methods will appear 6 
morphologically identical (Supplementary Fig. 4a).  7 
 8 
Cell culture: Changing media for CO lines for maintenance 9 
Timing 20 minutes 10 
Critical step: Once primary cholangiocytes have been isolated and plated as described above, culture 11 
conditions for all CO lines are the same and the following procedural steps for CO maintenance (steps 12 
15-30) apply equally to all CO lines, regardless of tissue of origin or derivation method. Equally, the 13 
characterisation data shown in Fig. 6 is representative of CO lines derived from all tissue types or 14 
derivation methods 15 
11. Media should be changed approximately every 48 hours. 16 
12. Prepare 1ml of William’s E+ media per well supplemented with 500 ng/ml Rspondin, 50 ng/ml 17 
EGF and 100 ng/ml DKK-1 to each  well of a 24 well plate. Additionally, 50 ng/ml of HGF and 18 
2 μM of FSK can be added optionally for slow growing lines requiring > 5-7 days between 19 
passages. [Troubleshooting] 20 
13. Carefully aspirate the old media from the well 21 
Critical step: tilt the plate when aspirating and aspirate from the edge of the well to avoid disrupting the 22 
Matrigel dome 23 
14. Add the new media to all the wells using a 5 ml or 10 ml pipette.  24 
Critical step: When adding media, tilt the plate and hold the pipette against the side of the well to avoid 25 




Passaging of CO lines for maintenance 1 
Timing: 90 minutes 2 
15. CO lines should be passaged approximately once every five days. However, the optimal time 3 
for passaging should be decided based on the confluency of the organoids, therefore the cells 4 
should be examined daily. (Fig. 5b, Image 1) 5 
Critical step: Allowing the wells to become too confluent may lead to collapse of organoids and 6 
subsequent cell death (Supplementary Fig. 4b, Image 2) 7 
16. Remove the media and add 500 μl of cell recovery solution to each well. The pipette should be 8 
aimed at the centre of the Matrigel dome and the cell recovery solution should be ejected 9 
forcefully to disrupt the surface of the dome.  10 
17. Mechanically dissociate the remaining Matrigel dome by scraping with a p1000 pipette (Fig. 5a, 11 
step 1) 12 
Critical step: Ensure that the whole surface of the well has been scraped to remove as many cells 13 
as possible 14 
18.  Transfer the cells from each well to a 15 ml centrifuge tube 15 
19. Wash each well with 500 μl of cell recovery solution 16 
Optional step: The same 500 μl can be carried across to each of the wells at this step to 17 
minimize the volume of cell recovery solution required for the washes 18 
20. Incubate the cells on ice at 4 °C for 30 minutes to fully dissolve the Matrigel 19 
21. Centrifuge at 444 g for 4 minutes at room temperature [Troubleshooting] 20 
22. Aspirate the supernatant 21 
23. Optional: If appropriate, use this wash step to split the cell pellet in multiple fractions.  22 
Critical step: We recommend the splitting the pellet appropriately to allow the generation of a 23 
single plate of organoids from a single pellet fraction. This is important to avoid prolonged use 24 
of the Matrigel master mix in following steps. This can lead to Matrigel solidification and 25 
gravitation of larger cell clumps to the bottom of the mix, compromising uniform distribution of 26 
cells and seeding density. 27 
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24. Resuspend in WE+ media mixing well using the following formula to calculate the minimum 1 
volume of media required: 2 
Volume of media to add (ml) = number of pellets to be made after splitting 3 
Example: For a 1:4 split, resuspend in 4 ml of media 4 
25. Aliquot the cell suspension into  multiple 15 ml centrifuge tubes adding 1ml per tube (e.g. for a 5 
1:4 split, share the 4 ml volume equally between four 15 ml centrifuge tubes) 6 
Critical step: CO pellets can typically be split between 1:4-1:6, depending on the number of wells in 7 
the initial plate and their confluency (Fig. 5a). For reference, Fig. 5b, Image 4 depicts a 8 
representative pellet for plating 9 CO wells (approximately 4.0 x 105 cells), obtained after a 1:4 split 9 
26. Centrifuge at 444 g for 4 minutes at room temperature  10 
27. Optional: CO pellets can be cryopreserved at this point if necessary by resuspending in 1 ml of 11 
CellBanker2, transferring to a 2 ml cryovial and freezing immediately at -80 °C.  12 
Critical step: For long-term cryopreservation, COs should be stored in a liquid nitrogen cryobank. 13 
Cryopreserved COs can be stored short-term at -80 °C but long-term storage at this temperature 14 
will affect the viability and overall health of the line 15 
28. Resuspend the pellet in a volume of 3X supplemented Williams E+ medium (supplemented 16 
with 1.5 μg/ml Rspondin, 150 ng/ml EGF, 30 μM (3 μl/ml) Y27632 and 300 ng/ml DKK-1) as 17 
described in Step 5. See the “preparation of a 3X supplemented William’s E+ solution” in 18 
Reagent Setup for instructions on how to prepare this solution and how to determine the 19 
appropriate volume to add.  20 
Critical step: The number of plated wells of COs depends on the size of the resulting cell pellet. E.g. 21 
a pellet of approximately 4.0 x 105 cells should be plated in 9 wells (Fig. 5b, Image 4). 22 
29. Mechanically dissociate the pellet to break up the organoids, using a p200 pipette. This should 23 
typically be done around 30-50 times although the exact number will vary according to the 24 
starting size of the organoids. [Troubleshooting] 25 
Critical step: Organoids must be dissociated into small clumps of approximately 10-20 cells to allow 26 
cysts to reform after splitting (Fig. 5b, Image 5). Mechanical dissociation should be done slowly to avoid 27 
damaging the cells 28 
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Critical step: Organoid breaking must be carried out with a p200 pipette, even if the volume of 3X 1 
William’s E+ media required exceeds 200 μl. In that case, add the initial 200 μl and break the organoids 2 
as described in step 29 before adding the remaining volume of media.  3 
30. Plate the organoids onto a pre-heated 24 well tissue culture plate as described in steps 3-10 4 
[Troubleshooting] 5 
Critical step: Organoids should reform from small clumps into organoids 24-48 hours hours after plating 6 
(Fig. 5b, Image 7(ii), enlarged Image in Supplementary Fig. 2, Image 2). Organoids should proliferate 7 
rapidly and should reach approximately 80% confluence 5 days after plating.  8 
 9 
Generation of densified collagen scaffolds 10 
Densified collagen scaffolds can be prepared to yield a sheet or tubular form. The sheet form produces 11 
a structure which has well a defined thickness and density, and yields highly reproducible scaffolds 12 
owing to the controlled nature of the process, while the collagen tube method is more technically 13 
challenging. 14 
Preparation of 5 mg/ml Collagen Gel 15 
Timing: 10 minutes 16 
Critical step: A collagen gel is produced by first mixing a collagen gel precursor solution. This 17 
neutralizes the pH of the stock collagen solution, and raises the ionic content, which induces 18 
the collagen fibrils to form a gel. Here we produce two collagen sheets by preparing 2.5 ml of 19 
collagen precursor solution, which is prepared to a final collagen concentration of 5 mg/ml. 1 ml 20 
of this volume is sufficient to produce a collagen scaffolds of a reproducible thickness 21 
(approximately 750 μm), using the recommended specimen tubes. The quantities in brackets 22 
represent the volumes required for a final volume of 2.5 ml; enough for two collagen sheets. 23 
 24 
Critical step: All equipment and reagents need to be sterilized before use and the following steps need 25 




31. Transfer 10x M199 at 10 %(vol/vol) final volume to a sterile 50 ml tube (0.25 ml). 1 
32. Calculate the volume of stock collagen solution required to yield a final collagen concentration 2 
of 5 mg/ml (1.25 ml). This is calculated by: 3 
Volume stock collagen [ml] =  5 [𝑚𝑚𝑚𝑚 𝑚𝑚𝑚𝑚⁄ ]
stock collagen concentration [𝑚𝑚𝑚𝑚 𝑚𝑚𝑚𝑚⁄ ]
 × precursor solution final volume [ml]  4 
33. Add sterile 1 M NaOH solution to the precursor solution at 2.5 % (vol/vol) the volume of stock 5 
collagen solution to be added (31 μl). 6 
34. Add sterile 7.5 % (wt/vol) sodium bicarbonate solution to the precursor solution at 3 %(vol/vol) 7 
the final volume (75 μl). 8 
Critical step: This volume makes up a constituent volume of the collagen gel precursor solution and so 9 
must be accurate or the concentration of collagen after gelation will vary. 10 
35. Using a 1 ml syringe, transfer stock collagen solution, at pre-calculated volume, to precursor 11 
solution (1.25 ml). [Troubleshooting] 12 
Critical step: Stock collagen solution will be viscous due to high concentration; use a syringe rather than 13 
a pipette to transfer the collagen accurately. 14 
36.  Shake the collagen precursor solution vigorously until of a uniform colour. [Troubleshooting] 15 
37. Calculate the remaining volume of cell medium to be added to the precursor solution to reach 16 
the required final volume (0.894 ml) and transfer to Falcon tube. 17 
38.  Centrifuge collagen precursor solution at 200 g for 1 min at 4 ºC in order to remove air bubbles 18 
and return the liquid to the bottom of Falcon tube. 19 
  20 
39. Generation of densified collagen scaffolds 21 
Critical step: Collagen scaffolds can be generated either as flat sheets or as tubes (Fig. 1c). For 22 
fabrication of flat collagen sheets, see Step 39, Section A. For Fabrication of collagen tubes, see Step 23 
39, section B 24 
Step 39, Section A: Fabrication of Densified Collagen Sheets 25 
Timing: 1 hour 30 minutes- 2 hours  26 
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Critical step: Larger-sized densified collagen sheets are possible with larger (flat-bottomed) containers 1 
(e.g. a 24 well plate). In order to produce collagen sheets of the same thickness, the collagen precursor 2 
solution should be poured into the container such that the height of the solution is 25 mm.  3 
I. Using a 1 ml syringe and 18G needle, transfer the 5 mg/ml collagen precursor solution to a 4 
specimen tube until the height of the solution is 25 mm (Fig. 7b, Image 1). Repeat as 5 
necessary. 6 
Critical step: Avoid inserting air bubbles into the mixture. Add collagen solution slowly. 7 
II. Gel the collagen solution by placing the specimen tube in a 37 °C incubator for 30 min. 8 
[Troubleshooting]  9 
Critical step: To maintain sterility transfer the specimen tube within an upside down 15 ml falcon 10 
tube 11 
III. Tightly roll three sheets of absorbent paper towels into a cylinder, roughly 5 mm in diameter 12 
and secure with autoclave tape.  13 
IV. Using scissors, cut the paper cylinder to 25 mm in length. Flatten end by pushing cylinder 14 
against a sterile surface (i.e. a 10cm plate). Autoclave both paper cylinder and nylon 15 
membrane. 16 
Critical step: The paper cylinder must have a flat edge in order to suitably contact and thus dry the 17 
collagen gel evenly. 18 
V. Using scissors, cut a piece of nylon membrane into a round piece of a slightly lower diameter 19 
than the specimen tube.  20 
VI. Return the specimen tube to the tissue culture hood. Carefully place the nylon membrane on 21 
top of the gel and then place the paper towel wadding into the specimen tube, on top of the 22 
membrane (Fig. 7b, Image 2(i)). 23 
VII. Apply very light finger pressure on the top of the wadding so as to make good contact with the 24 
gel and then leave to densify for approximately 1 hour (Fig. 7b, Images 1-3(i)). 25 
[Troubleshooting]  26 
VIII. Monitor the densification process every 5-10 minutes to ensure the wadding is in contact with 27 
the gel and occasionally apply light pressure to keep the wadding in place. [Troubleshooting] 28 
Critical step: Applying too much pressure will rip the top surface of the gel.  29 
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IX. The densification is terminated when the paper towel has almost reached the bottom of the 1 
specimen tube and water cannot be removed any further (Fig. 7b, Image 3(ii)). Once this has 2 
occurred, remove the paper wadding; the collagen gel and nylon membrane should be adhered 3 
to the wadding. [Troubleshooting] 4 
X. Using tweezers, carefully grip the edge of the collagen sheet and peel it away from the paper 5 
wadding. 6 
XI. The nylon membrane is likely to remain attached to the collagen sheet. By gripping the nylon 7 
sheet with tweezers, this can also be peeled away from the collagen sheet (Fig. 7b, Image 4) 8 
[Troubleshooting] 9 
Critical step: Avoid ripping the collagen sheet by gently peeling it away from the nylon membrane. 10 
XII. Transfer 4 ml of William’s E+ media or PBS to a 6 well plate, and then transfer the densified 11 
collagen sheet to the 6 well plate (Fig. 7b, Image 5). For larger collagen sheet preparations, 12 
transfer to an appropriately-sized container. 13 
XIII. For storage, place the plate containing the densified collagen sheet at 4 °C. Warm to 37 °C 14 
prior to cell seeding, by placing it in the incubator. 15 
XIV. Cells can be seeded onto the surface of the collagen sheet at this point and cultured for several 16 
months. 17 
 18 
Step 39, Section B: Fabrication of Densified Collagen Tubes 19 
Timings: 5 – 25 hours 20 
I. Using a 1 mL pipette, transfer the precursor solution to the densification chamber until the 21 
chamber is full (approximately 1.5 mL) (Fig. 8c, Image 1). 22 
Critical step: Avoid inserting air bubbles into the mixture. Add collagen solution slowly. 23 
II. Gel the collagen solution by placing the densification chamber in a 37 °C incubator for 30-24 
60 minutes. [Troubleshooting] 25 
III. In order to form a collagen tube, it is necessary to dislodge the collagen gel from the top of 26 
the funnel to encourage the gel surface to drop. Thus, using a sterile pair of tweezers under 27 
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a sterile hood, gently peel the collagen gel away from the walls of the chamber (Fig. 8c, 1 
Image 2). 2 
IV. Loosen the screws attaching the base to the funnel. 3 
V. Return the densification chamber to the incubator. Monitor the chamber regularly for 30 min 4 
until the level of the collagen gel drops to the top of the metallic wire (Fig. 8c, Image 3). 5 
Critical step: The top end of the metallic wire, embedded in the collagen, will prevent the gel surface 6 
dropping further. Water will continue to be removed through evaporation around the sides of the 7 
funnel to yield a tubular structure. [Troubleshooting] 8 
Critical step: There should be a visible gap between the collagen gel and the edges of the funnel. 9 
VI. Monitor the densification chamber in the incubator for a further 4-24 hours to allow for 10 
evaporation of the water phase of the gel (Fig. 8b, panel 4). 11 
Critical step: It is important to monitor the collagen gel and prevent the tube from over-drying, based 12 
on the humidity conditions of the incubator. 13 
VII. Continue the process until the vast majority of water has evaporated. The collagen scaffold 14 
should consist of a dense and thin cylindrical component around the wire core, with a larger 15 
region near the top of the funnel. (Fig. 8c, Image 4). [Troubleshooting] 16 
VIII. Transfer 4 mL of William’s E+ media to a 6 well plate. 17 
Taking a sterile pair of tweezers, grip the top of the collagen tube and slowly pull it upwards 18 
over the end of the metallic wire (Fig. 8c, Image 5). [Troubleshooting]  19 
Critical step: Be careful not to damage the collagen tube with the tweezers or the end of the metallic 20 
wire. 21 
IX. Place collagen tube in 6 well plate for storage. The pink colouration will disappear from the 22 
collagen tube over several hours (Fig. 8d, Images 1 and 2). 23 
X. Prior to surgical implantation, it is necessary to trim away the excess collagen sheet and cut 24 
a suitable length of tube for the experiment. Place the tube under a dissecting microscope 25 
and, using a surgical scalpel, cleanly trim any excess collagen (Fig. 8d, Image 3).   26 
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XI. Determine a suitable length of collagen tube along the scaffold. Pick a region which is 1 
cylindrical in nature (likely the middle section). Using a surgical scalpel, cleanly cut across 2 
the tube to yield the required length for the particular application. (Fig. 8d, Image 4). 3 
Critical step: Trimming the tube is a particularly difficult step, likely requiring the assistance of an 4 
experienced surgeon. Be extremely careful not to cut into the lumen of the tube. Doing so will result in 5 
leakages when the tube is perfused. 6 
XII. Observe patent lumen under phase contrast using inverted microscope (Fig. 8d, Image 5) 7 
XIII. Transfer the densified collagen tube to the 6 well plate. 8 
XIV. Store the collagen tube in William’s E+ medium in the incubator until ready. The surface of 9 
the tubes can be further seeded with cells at this point. 10 
 11 
40. Seeding COs onto scaffolds 12 
Critical step:  The use of an optimal CO line is essential for scaffold seeding. Suboptimal lines will 13 
result in reduced cell attachment, proliferation and long-term viability. All CO lines should express the 14 
biliary markers CK19, CK7, Sox9 and GGT (Fig. 6a and 6b) and display ALP and GGT activity (Fig. 15 
6c and 6d). Healthy CO lines should require passaging every five days (Fig. 5b, Image 1). CO lines 16 
that fail to meet these criteria should not be considered for scaffold seeding. See Troubleshooting for 17 
steps 10, 12, 29 and 30 for guidance on how to improve the quality of a suboptimal CO line.  18 
Critical step: For seeding COs onto densified collagen sheets, see Step 40, Section A. For seeding COs 19 
onto densified collagen tubes, see Step 40, Section B. For seeding COs onto PGA scaffolds, see Step 20 
40, Section C (Fig. 1d). 21 
Step 40, Section A: Seeding on densified collagen sheets 22 
Timing: 2 hours 30 minutes - 4 hours 23 
Critical step: Collagen scaffolds must be of an optimal quality to be used for seeding. Batch test the 24 
stock collagen solution used for collagen densification for cell attachment and proliferation and ensure 25 
that the densification process has completed fully (see Troubleshooting for Step 39, Section A) and the 26 
scaffold has not dried out during storage to ensure the quality of the collagen scaffolds 27 
42 
 
Critical step: For long term storage, the collagen scaffolds are maintained in PBS to prevent them from 1 
drying out.  2 
I. Remove the PBS and place the collagen scaffold in a 24 well tissue culture plate, then place it 3 
in the incubator for 30 minutes to 1 hour, or until the PBS is evaporated and residues on the 4 
surface are no longer visible. 5 
Critical step: The excess presence of liquid on the scaffold’s surface may prevent cell attachment 6 
Critical step: Allowing the scaffold to dry for a prolonged period following evaporation of the PBS may 7 
affect the collagen fibre micro-architecture. 8 
II. Remove the organoids from the Matrigel domes using cell recovery solution and incubate on 9 
ice for 30 minutes as described in steps 16-26. An optimal seeding density of 1.5x106 cells/cm2 10 
has been observed to give confluent scaffolds over a short period of time; the number of wells 11 
required for a certain surface area can be calculated with the given formula:  12 
III.  13 
𝑛𝑛𝑛𝑛. 𝑛𝑛𝑜𝑜 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 = 𝑐𝑐𝑐𝑐𝑠𝑠𝑜𝑜𝑜𝑜𝑛𝑛𝑐𝑐𝑠𝑠 𝑐𝑐𝑠𝑠𝑠𝑠𝑜𝑜𝑠𝑠𝑐𝑐𝑐𝑐 (𝑐𝑐𝑐𝑐2) ×  1.5 × 106𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐/𝑐𝑐𝑐𝑐2 14 
IV. Aspirate the supernatant and resuspend the pellet in an adequate volume of William’s E+ media 15 
supplemented with 500 ng/ml Rspondin, 50 ng/ml EGF, 100 ng/ml DKK-1 and 10 μM Y27632. 16 
Critical step: For the seeding solution a cell density of 5 x 104 cells/μl is recommended. E.g. a pellet of 17 
1x106 cells, equivalent to approximately 10 confluent wells, is resuspended in a volume of 20 µL. 18 
Once seeded on a scaffold surface of 0.65 cm2 this should allow to reach a confluent layer of cells in 19 
approximately 2 weeks’ time, with slight variations depending on the organoid line. 20 
V. Gently pipette up and down with a p20 pipette 30-40 times to mechanically dissociate the 21 
organoids in small clumps (approximately 10-20 cells per clump) and obtain a homogeneous 22 
solution. [Troubleshooting] 23 
VI. Seed the cells by directly pipetting this solution onto the scaffold’s surface with a p10 pipette 24 
(Fig. 9b, Image 3(i) and 3(ii)) [Troubleshooting] 25 
Critical step: In order to achieve a homogeneous attachment, seeding multiple aliquot of 5 µl in different 26 
positions all over the scaffold surface is recommended. 27 
43 
 
VII. After seeding on collagen scaffolds, keep the plate in a 37 °C incubator for 1-2  hours to allow 1 
the cells to attach to the scaffold 2 
Critical step: monitor the scaffolds every 30 minutes to avoid drying the cells out [Troubleshooting] 3 
VIII. Prepare 2 ml of William’s E+ media supplemented with 500 ng/ml Rspondin, 50 ng/ml EGF, 4 
100 ng/ml DKK-1 and 10 μM Y27632 for each scaffold 5 
IX. To add the media, tilt the plate and slowly add from the bottom of the well (Fig. 9b, Image 5) 6 
[Troubleshooting] 7 
Critical step: Media must be added as slowly as possible, using a P1000 pipette. Care must be taken 8 
to avoid disrupting the scaffold when adding media 9 
X. The seeded scaffold should be kept in culture for 4 days before the first media change, in order 10 
to maximize cell attachment. After this period, 500 µl of William’s E+ media supplemented with 11 
500 ng/ml Rspondin, 50 ng/ml EGF and 100 ng/ml DKK-1 are changed every other day. 12 
[Troubleshooting] 13 
Critical step: When changing the media, all previous media must first be aspirated. Care must be 14 
taken to avoid disrupting the scaffold during media aspiration 15 
Critical step: COs will start growing and expanding on the scaffold after a first lag phase (lasting 16 
approximately 4-5 days after seeding), then confluency should be reached in approximately 2 17 
weeks, according to the age of the cell line.  18 
Step 40, Section B: Seeding onto the lumen of densified collagen tubes  19 
Timings: 2 hours 30 minutes- 3 hours 30 minutes 20 
 21 
I. Working under aseptic conditions, transfer the densified collagen tube onto a dry 10 cm plate   22 
II. leave to dry under a tissue culture hood for approximately half an hour, or until almost all the 23 
residual PBS has evaporated 24 
III. Passage the organoids as described in steps 16-26. 25 
Critical step: Preparation of the CO cell suspension (steps III-IV) can be done during the waiting step 26 
described in step II 27 
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IV. Resuspend the cells in 25 μl of William’s E+ media with 50 ng/ml EGF and 10 μM Y27632 1 
V. Using a p20 pipette, carefully break the COs into small clumps (10 – 20 cells) 2 
[Troubleshooting] 3 
Critical step: failure to break the COs into small enough clumps (Supplementary Fig. 2, Image 2) will 4 
result in the cells failing to form a confluent monolayer on the luminal surface of the tube  5 
VI. Using a 34 G Hamilton removable needle and a pair of fine forceps, cannulate the tube with 6 
the 34 G needle. For best results, this should be done under a dissecting microscope (Fig. 7 
10b, Image 2) 8 
Critical step: Cannulation of the tube should ideally be performed by an experienced surgeon. 9 
Improper attempts at cannulation can result in disruption of the construct wall beyond repair. 10 
VII. Using a p200 pipette, transfer the cell suspension into a 25 μl or 50 μl Hamilton syringe 11 
Critical step: it is highly advisable to use Hamilton syringes, as recommended in the equipment list, or 12 
some other model of small volume syringes with removable needles and no dead space. This is due 13 
to the very low volume of cell suspension required for seeding, which is smaller than the dead space 14 
in standard needles 15 
VIII. Slowly depress the plunger on the syringe to deposit the cell suspension in the lumen of the 16 
tube while simultaneously removing the needle from the tube in order to distribute the cells 17 
evenly along the tube lumen (Fig. 10b, Image 3) [Troubleshooting] 18 
IX. Incubate the freshly seeded tube in a covered 10 cm plate at 37 °C without media for up to an 19 
hour to allow cell attachment [Troubleshooting] 20 
X. Transfer the tube to a 6 well plate  21 
XI. Prepare 2 ml of William’s E+ media supplemented with 500 ng/ml Rspondin, 50 ng/ml EGF, 22 
100 ng/ml DKK-1 and 10 μM Y27632 23 
XII. Using a P1000 pipette, tilt the plate and add the media slowly to the side of the well, until the 24 
tube is covered [Troubleshooting] 25 
Critical step: Media must be added as slowly and carefully as possible, to avoid disruption of the 26 
newly attached cells. Care must be taken to avoid touching the tube with the pipette  27 
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XIII. The seeded tube should be kept in culture for 4 days before the first media change, in order 1 
to maximize cells attachment. After this period, 2 ml of William’s E+ media supplemented with 2 
500 ng/ml Rspondin, 50 ng/ml EGF and 100 ng/ml DKK-1 are changed every 4 days in order 3 
to reduce the disruption caused by media change. [Troubleshooting] 4 
Critical step: When changing the media, all previous media must first be aspirated. Care must be 5 
taken to avoid disrupting the tube during media aspiration. 6 
Critical step: The construct is kept in culture and a confluent layer of cells should be reached in 7 
approximately 4 weeks’ time, depending on the age of the cell line (Fig. 10c and 10d). 8 
 9 
Step 40, Section C: Seeding on PGA scaffolds 10 
Timings: 3 hours 30 minutes - 4 hours  11 
I. PGA scaffolds are available commercially (see Materials list) and can be stored until needed.  12 
II. Place the PGA scaffold, with a thickness of 1 mm and density of 50 mg/cm3, in 1 M NaOH for 13 
10-30 seconds 14 
III. Sterilize the scaffold by immersion in 70% ethanol for 30 minutes. 15 
IV. Air-dry the PGA scaffold in a 6 well tissue culture plate under a sterile tissue culture hood for a 16 
further 30 minutes (Fig. 9c, Image 1). 17 
Critical step: Ensure that all traces of NaOH and ethanol are gone from the scaffold before 18 
beginning seeding. Improper drying can lead to cell death and failure to attach to the scaffold 19 
V. Remove the COs from organoid culture and prepare a suspension of small clumps as 20 
described in step 40, Section A II-V [Troubleshooting] 21 
Critical step: Given the pores size of the electrospun PGA it is important that the CO clumps are 22 
no smaller than 40-60 cells per clump, as small cell clumps will fall through the pores of the 23 
scaffold and not be retained.  24 
VI. Gently pipette up and down with a p20 pipette 10-20 times in order to have a homogeneous 25 
cells suspension of with CO clumps of approximately 40-60 cells per clump.  26 
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VII. Seed the cells onto the PGA scaffold as described in step 40, section A VI-X (Fig. 9c, Images 1 
3(i) and 3(ii)). [Troubleshooting] 2 
 3 
41. Characterisation of cholangiocyte organoids 4 
41. For analysis of COs through immunofluorescence, see Step 41, Section A. For analysis through 5 
flow cytometry, see Step 41 Section B. For RNA extraction from COs for qPCR, see Step 41, 6 
Section C. 7 
Step 41, Section A: Immunofluorescence 8 
I. Day 1: Aspirate William’s E+ culture medium 9 
II. Add 1 ml of 4 % PFA (vol/vol) per well  10 
Critical step: PFA should be added gently to the side of the well to not disrupt the Matrigel dome 11 
III. Incubate at 4 °C for 20 minutes to fix the cells [Troubleshooting] 12 
IV. Aspirate the PFA 13 
Critical step: PFA should be aspirated with a p1000 pipette to avoid disruption to the Matrigel 14 
dome 15 
V. Wash twice in PBS. Each wash should take 10 minutes 16 
Pause Point: The CO plate can be sealed and kept at 4 °C for up to four weeks 17 
VI. Prepare a solution of 10% (vol/vol) donkey serum and 0.1% (vol/vol) TritonX-100 in PBS. 18 
[Troubleshooting] 19 
VII. Add 1 ml of this solution to each organoid well and incubate at room temperature  for one 20 
hour to block and permeabilise the COs [Troubleshooting] 21 
VIII. Dilute the primary antibodies in a solution of 1% (vol/vol) donkey serum and 0.1% (vol/vol) 22 
TritonX-100 in PBS. 23 
IX. Add 500 μl of primary antibody solution per CO well 24 
X. Stain the COs overnight at 4 °C  25 
XI. Day 2: wash the COs three times with 1% (vol/vol) donkey serum and 0.1% (vol/vol) TritonX-26 
100 in PBS. Each wash should take 45 minutes 27 
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XII. Dilute the secondary antibodies in a solution of 1% (vol/vol) donkey serum and 0.1% (vol/vol) 1 
TritonX-100 in PBS. 2 
XIII. Add 500 μl of secondary antibody solution per CO well 3 
XIV. Stain the COs overnight at 4 °C [Troubleshooting] 4 
XV. Critical step: CO plates should be wrapped in foil to prevent exposure of the secondary 5 
antibody to light 6 
XVI. Day 3: aspirate the secondary antibody solution 7 
XVII. Prepare a solution of Hoechst 33258 1:10,000 (vol/vol) in PBS 8 
XVIII. Incubate the COs in this Hoecscht 33258 solution for 10 minutes at room temperature 9 
[Troubleshooting] 10 
XIX. Aspirate the Hoecscht 33258 solution 11 
XX. Wash the COs three times with PBS. Each wash should take 45 minutes 12 
XXI. Add a final 1 ml of PBS per CO well and Image the COs immediately or store the plate at 4 °C 13 
until ready for analysis 14 
XXII. Image using a confocal microscope. All IF images (Figs. 6a and Fig. 11a, 11c and 11e) were 15 
acquired using a Zeiss LSM 700 confocal microscope. Imagej 1.51h software (Wayne 16 
Rasband, NIHR, USA, http://Imagej.nih.gov/ij) was used for Image processing such as 17 
merging of different channels. 18 
 19 
Step 41, Section B: Flow Cytometry 20 
Timings: 3-5 hours 21 
Preparation of a single-cell suspension 22 
I. Passage organoids as described in steps 16-24 23 
II. Resuspend the pellet in 1 ml of William’s E+ media and centrifuge at 444g for 4 minutes 24 
III. Prepare a solution of Accutase (pre-warmed to 37 °C) with 4 mg/ml of DNase I and 10 μM 25 
Y27632 26 
Critical step: Omission of DNase I and Y27632 can lead to cell clumping and greatly reduce viability 27 
IV. Aspirate the supernatant and resuspend the pellet in 1 ml of Accutase solution 28 
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V. Incubate the cells at 37 °C for up to five minutes to produce a single-cell suspension 1 
[Troubleshooting] 2 
Critical step: Examine the cells under a microscope halfway through to check the progress of the 3 
dissociation 4 
VI. Add 1 ml of William’s E+ media or PBS 1% BSA (wt/vol) with 4 mg/ml of DNase I and 10 μM 5 
Y27632 to the cell suspension 6 
VII. Centrifuge the cells at 444 g for 4 minutes at room temperature 7 
VIII. Resuspend the pellet in 1 ml of William’s E+ media or PBS 1% BSA (wt/vol) with 4 mg/ml of 8 
DNase I and 10 μM Y27632 9 
IX. Filter through a 40 μm filter [Troubleshooting] 10 
Critical step: If performing flow cytometry on a live cell population, skip steps X-XV and go directly to 11 
steps XVI-XXIX (staining of a single cell suspension for flow cytometry) 12 
X. Centrifuge the cells at 444 g for 4 minutes at room temperature 13 
XI. Resuspend the pellet in 1 ml of 4% PFA (vol/vol) 14 
XII. Incubate the cells at 4 °C for 15 minutes to fix the cells 15 
XIII. Add 1 ml of PBS 1% BSA (wt/vol) 16 
XIV. Centrifuge the cells at 444 g for 4 minutes at room temperature 17 
XV. Resuspend the pellet in 1 ml of PBS 1% BSA (wt/vol) 18 
Critical step: Cells should be handled very carefully after fixation to avoid damage. Pellets should be 19 
resuspended by flicking the centrifuge tube (as opposed to pipetting) and all pipetting should be done 20 
slowly 21 
Staining a single cell suspension for flow cytometry 22 
XVI. If staining for cell-surface markers only, prepare a 1 in 20 dilution of FcR block in PBS 1% BSA 23 
(wt/vol) 24 
XVII. If staining for intracellular markers, prepare a 1 in 20 dilution of FcR block in PBS 1% BSA 25 
(wt/vol) with 0.1% Triton X (vol/vol) 26 
XVIII. Centrifuge the cells at 444 g for 4 minutes at room temperature and resuspend the pellet in 200 27 
μl ml of diluted FcR block 28 
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XIX. Incubate at room temperature for 30 minutes 1 
Critical step: An aliquot of the cell suspension (at least 1 x 105 cells) should be used as an unstained 2 
control. If using separate primary and secondary antibodies, a further aliquot must be used for a 3 
secondary-only control. Both aliquots should be kept at 4 °C until required 4 
XX. Prepare a master mix of all antibodies (if using conjugated antibodies) or all primary antibodies 5 
(if using separate primary and secondary antibodies) in PBS 1% BSA (wt/vol) 6 
XXI. Centrifuge the cells at 444 g for 4 minutes at room temperature 7 
XXII. Resuspend the pellet in 200 μl of master mix solution 8 
XXIII. If using conjugated antibodies, incubate at 4 °C for half an hour. If using primary antibodies, 9 
incubate at room temperature for an hour 10 
XXIV. If using conjugated antibodies, wash the cells three times in PBS 1% BSA (wt/vol) and filter 11 
through a 40 μm filter before analysing the sample on the flow cytometer 12 
XXV. If using unconjugated antibodies, wash the cells three times in PBS 1% BSA (wt/vol). Each 13 
wash should take 5 minutes 14 
XXVI. Prepare a solution of all secondary antibodies in PBS 1% BSA (wt/vol) 15 
XXVII. Resuspend the cells in 200 μl of secondary antibody solution and incubate at room temperature 16 
for one hour.  17 
Critical step: The secondary-only control should also be stained at this point 18 
Critical step: The cells should be kept in the dark to prevent exposure of the secondary antibody to 19 
light 20 
XXVIII. Wash the cells three times in PBS 1% BSA (wt/vol). Each wash should take 5 minutes 21 
XXIX. Resuspend the cells in 200 μl of PBS 1% BSA (wt/vol) and filter through a 40 μm filter before 22 
analysing the sample on the flow cytometer. All flow cytometric analyses were performed on a 23 
FACS Cyan flow cytometer and analysed using FlowJo version 10.4.2. 24 
 25 
Step 41, Section C: RNA extraction  26 
Timings: 2 hours 27 
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I. If isolating RNA from an established CO line, first remove COs from organoid culture as 1 
described in steps 16-25. If isolating RNA from a suspension of primary cells, go straight to 2 
step II 3 
II. Centrifuge the cells at 444 g for 4 minutes 4 
III. Aspirate the supernatant and resuspend the pellet in 350 μl of RNA lysis buffer.  5 
Critical step: Ensure the lysed cell suspension is fully homogenised 6 
IV. Transfer the lysed cell suspension into a pre-labelled 1.5 ml Eppendorf tube and store the tube 7 
immediately at -80 °C [Troubleshooting] 8 
Critical step: Delay in transferring the lysed sample to -80 °C storage can result in degradation of RNA 9 
quality 10 
Pause Point: Samples in RNA lysis buffer can be stored at -80 °C for > 1 year until needed 11 
V. Thaw samples on ice  12 
VI. Use the Sigma Aldrich “GenElute™ Mammalian Total RNA Miniprep Kit” to extract RNA from 13 
the samples according to the manufacturer’s instructions 14 
 15 
Timings 16 
These timings are estimated based on the approximate time required for a researcher with experience 17 
in this protocol to complete each of the steps. When attempting this protocol for the first time, 18 
researchers may find that aspects of the procedure take longer to complete. 19 
Step 1, tissue collection: 1-8 hours 20 
Step 2 section A, derivation of extrahepatic cholangiocyte organoids from deceased organ 21 
donors: 1-2 hours (Washing, dissecting and scraping the tissue (steps I-VIII): 20-30 minutes; wash 22 
steps and optional red blood cell lysis (steps IX-XII): 20-40 minutes; organoid plating (steps XIII-XX): 23 
40 minutes) 24 
Step 2 section B, derivation of extrahepatic cholangiocyte organoids through Endoscopic 25 
retrograde cholangiopancreatography (ERCP) brushings: 30 minutes 26 
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Step 2 section C, derivation of intrahepatic cholangiocyte organoids from liver tissue: 30-40 1 
minutes (Tissue dissection (steps I-II): 10-20 minutes; washing and plating preparation (steps III-VI): 2 
10-15 minutes; plating (steps VII-VIII): 10 minutes) 3 
Step 2 section D, derivation of intrahepatic cholangiocyte organoids through EpCAM+ MACS 4 
sorting: 2-3 hours (Preparing the tissue for digestion (steps I-III): 10 minutes; digestion and filtering 5 
(steps IV-VII): approximately 1 hour; red cell lysis, washing and cell counting (steps VIII-XVI): 20-30 6 
minutes; MACS sorting and plating (steps XVII-XXVII): approximately 1 hour) 7 
Steps 3-10, plating of primary cholangiocytes in organoid format: 10-40 minutes 8 
Steps 11-14, changing media for CO lines for maintenance: 20 minutes 9 
Steps 15-30, passaging of CO lines for maintenance: 90 minutes (Removing organoids from 10 
Matrigel (steps 15-21): 40 minutes; washing and splitting the pellet (steps 22-26): 10 minutes; plating 11 
the cells (steps 28-30): 45 minutes) 12 
Steps 31-38, preparation of 5 mg/ml collagen gel: 20 minutes 13 
Section 39A: Fabrication of Densified Collagen Sheets: 1 hour 30 minutes-2 hours (Preparation 14 
of the densification chamber (steps I-VI): approximately 45 minutes; collagen densification (steps VII-15 
IX): 1 hour; removal and storage of the densified collagen scaffold (steps X-XIV): approximately 10 16 
minutes) 17 
Section 39B: Fabrication of Densified Collagen Tubes: 5-27 hours (Loading chamber with 18 
collagen and gelation (steps I-II): 40 minutes-1 hour; collagen densification (steps III-VII): 4-24 hours; 19 
removal and storage of the densified collagen tube (steps VIII-XIV): approximately 30 minutes)  20 
Section 40A: Seeding on flat densified collagen scaffolds: 2 hours 30 minutes-4 hours (drying of 21 
the collagen scaffold (step I): 30 minutes-1 hour; preparation of the COs for seeding (steps  II-V): 45 22 
minutes; scaffold seeding (step V): 15 minutes; waiting step before media addition (step VII): 1-2 hours; 23 
media addition (steps VII-IX): 5 minutes) 24 
Section 40B: Seeding on densified collagen tubes: 2 hours 30 minutes-3 hours 30 minutes 25 
(drying of collagen tube (steps I-II): 30 minutes-1 hour; preparation of the COs for seeding (steps III-26 
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V): 45 minutes; tube cannulation and cell seeding (steps VI- VII): 30 minutes; cell attachment (Step 1 
IX): 30 minutes- 1 hour; Addition of media (steps IX- XII): 15 minutes 2 
Section 40 C: Seeding on PGA scaffolds: 3 hours 30 minutes - 4 hours (Preparation of the PGA 3 
scaffold (steps I-III): Approximately 1 hour; preparation of CO suspension (steps IV-V): 40 minutes; 4 
seeding of the PGA scaffold (step VI): 15 minutes; waiting step before media addition (step VI): 1-2 5 
hours; media addition (step VI): 5-10 minutes) 6 
Section 41 A: Immunofluorescence: 3 days (Organoid fixation (steps I-V): 40 minutes; blocking and 7 
primary antibody addition (steps VI-IX): approximately 90 minutes; primary antibody staining (step X): 8 
overnight; washing and secondary antibody addition (steps XI-XIII): approximately 2 hours and 30 9 
minutes; secondary antibody staining (steps XIV-XV): overnight; washing and nuclear staining (steps 10 
XVI-XXI): approximately 2 hours and 40 minutes) 11 
Section 41 B: Flow cytometry: 3 hours – 5 hours (Preparation of a single-cell suspension (steps I-12 
X): 60 minutes; fixation (steps XI-XV): 30 minutes; blocking (steps XVI-XIX): 45 minutes; staining with 13 
conjugated antibodies (steps XX- XXIV): 45 minutes; staining with separate primary and secondary 14 
antibodies (steps XXV- XXIX): 2 hours 30 minutes) 15 
Section 41 C: RNA extraction: 2 hours (cell lifting (steps I-II): 40 minutes; RNA lysis (steps III-IV): 16 
10 minutes; RNA extraction (steps V-VI): 1 hour) 17 
 18 
TROUBLESHOOTING  19 
 20 
Step Problem Explanation Solution 
Step 2, 
Section A III 
Very few or no 
cells are collected 
after mechanical 
dissociation 
Cell detachment during 
PBS washes 
1. Reduce the number of washes 
 
2. If the tissue has been in cold 
storage solution for longer than 2-4 
hours, consider omitting the wash 
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step. Aspirate any excess bile with a 
p1000 pipette instead 
 
3. Centrifuge the PBS to collect the 




Pellet contains too 
much debris 
Forceful scraping of the 
tissue can mechanically 
dissociate part of the 
fibrous tissue as well as 
biliary epithelia 
1. Scrape the tissue very gently and 
avoid scraping the same area of 
tissue more than twice 
 
2. Where possible, remove large 
debris with a p1000 pipette before 
centrifugation 
Step 2, 
Section A X 
Cells do not form a 
pellet in step X 
after mechanical 
dissociation 
1. Inadequate wash 
 
2. Remnants of bile and/or 
debris in the cell 
suspension 
1. Increase the number of PBS 
washes prior to mechanical 
dissociation 
 
2. Ensure that the tissue is 
adequately washed before starting 
mechanical dissociation 
 
2. Remove large pieces of debris 
using a p1000 pipette before 
transferring the cells to a 50 ml 
centrifuge tube 
Step 2, 
Section A X 
Cells are lost 
during the wash 
steps 
Washing was done in PBS 
or media with inadequate 
protein content  
Use only complete Williams E+ 
media during the wash steps or PBS 




Organoids do not 
form following 
plating 
Poor cell viability due to: 
 
1. Dissect the tissue as quickly as 
possible and submerge in media as 




Section B V 
 1. Tissue drying during 
the dissection  steps 
 
 2. Stress of mechanical 
dissociation 
 
3. Prolonged cold storage 
 
4. Lack of necessary 
cytokines in the media 
 
5. Poor quality of tissue 
culture media and 
reagents (Matrigel or 
cytokines) 
 
2. Avoid vigorous scraping of the 
tissue resulting in cell death 
 
2. Avoid vigorous washes and 
pipetting resulting in increased cell 
stress and/or death 
 
3. Process the tissue as soon as 
possible after surgical excision 
 
4. Ensure that the media contains 
150 ng/ml of EGF and 10 μM Y27632 
at every stage 
 
5. Batch test Matrigel and media 
components 
 
 Always store Matrigel and cytokines 
at -80 °C 
 
Avoid repeat freeze-thaw cycles of 
cytokines and do not use Matrigel 







Organoids do not 
form once the 
tissue is plated 
Poor cell viability due to: 
 1. Tissue drying during 
the dissection steps 
 
1. Complete the dissection step as 







 2. Stress of mechanical 
dissociation 
 
3. Prolonged cold storage 
 
4. Lack of necessary 
cytokines in the media 
 
5. Poor quality of tissue 
culture media and 
reagents (Matrigel or 
cytokines) 
2. Ensure the dissected liver pieces 
are as small as possible so they can 
fit into the tip of a p1000 pipette 
without difficulty 
 
3. Process the tissue as soon as 
possible after surgical excision 
 
4. Ensure that the media contains 
150 ng/ml of EGF and 10 μM Y27632 
at every stage 
 





Section D V 
 
Poor viability of 
cells before 
EpCAM+ sorting 
1. Prolonged enzymatic 
dissociation 
 
2. Vigorous pipetting to 
dissociate cell clumps 
resulting in cell death 
 
3. Prolonged cold storage 
 
 
1. Examine the cells every ten 
minutes during the dissociation. 
Ensure the dissociation is stopped as 
soon as a single cell suspension is 
obtained and the majority of liver 
cells have been released from the 
extracellular matrix (Supplementary 
Fig. 2b, Image 4) 
 
2. Dissociate cell clumps gently. 
Prolong enzymatic digestion if 




3. Process the tissue as soon as 






during or after 
dissociation to a 
single cell 
suspension 
DNA fragments in the 
suspension originating 
from non-viable cells 
cause cholangiocytes to 
clump  
1. Monitor the cells closely during 
dissociation. If cells show signs of 
clumping, increase the concentration 
of DNase I by 30% 
 
2. Following filtering the cells should 
be resuspended in PBS containing 
1% BSA (wt/vol) supplemented with 





Significant loss of 
cells after single 
cell dissociation 
Cell adhesion to the 
surfaces of the centrifuge 
tube during centrifugation 
or MACS sorting 
1. Resuspend cells in sterile PBS  
1% BSA (wt/vol) with 4 mg/ml of 
DNase I and 10 μM Y27632 
 
2. Prime centrifuge tubes with PBS 





the MACS sorting 
Cell  clumps remain in the 
cell  suspension 
Filter the sample immediately before 
running on the MACS cell sorter 
6 Matrigel does not 
form a dome but 
attaches to the 
side of the well 
during plating 
Remnants of solidified 
Matrigel blocking the 
pipette tip and preventing 
uniform dispensation of 
the gel 




Cells attach to the 
bottom of the plate 
1. Delay in inverting the 
plate after plating of the 
cells 






2. Delay in Matrigel 
solidification due to low 
plate starting temperature 
allowing cell clumps to 
gravitate to the bottom of 
the plate 
2. Ensure plating occurs on a plate 
heater to allow the Matrigel to solidify 
quickly as possible  
 
3. Keep the plates inverted for 30 




Cells form small 
spheres lacking a 
lumen after plating 
Overly dense initial 
plating, preventing 
organoid expansion  
1. Passage the cells earlier than 5 
days and plate at a reduced density 
 
2. Add 2 μM FSK to the media 
21 Matrigel remnants 
are present in the 




Incubation time was too 
short 
Ensure the cells have been 
incubated for the full 30 minutes in 
cell recovery solution and that the 
volume of ice is adequate to keep the 








signs of stress 
such as thickening 





Cell death is 
observed for 
several days after 
passaging/consist
1. Events during 
passaging could be 
causing stress to the cells: 
a. Dissociating the 
organoids too vigorously 
during step 29 
b. Prolonged duration of 
passaging, stressing the 
cells by delaying return to 
optimal culture conditions  
 
2. Suboptimal batch of 
Matrigel  
1a. Avoid vigorous dissociation of 
during passaging  
 
1b. Minimize delays during 
passaging 
 
2. Batch-test new lots of Matrigel  
 
3. Store all stock solutions at 4 °C 
and do not use stock solutions made 
more than 3 months previously 
Where applicable, do not use stock 
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3. Suboptimal quality of 






5. Delay in passaging the 
cells (Supplementary Fig. 
4b) 
 
6. Overly dense plating 
preventing organoid 
proliferation 
(Supplementary Fig. 4b) 
solutions beyond their expiry date.  
Store all cytokines at -80 °C 
 
4. Test organoid cultures for 
Mycoplasma contamination  
 
5. Passage COs when 80% confluent 
with no signs of organoid collapse, 
typically every five days. Plates 
should be observed daily to 
determine the optimum time for 
passaging 
 
6. Passage the cells earlier than the 
typical five days and ensure the cells 
are plated more sparsely next 
passage 
7. Increase the working 
concentration of EGF used during 
maintenance to up to 100 ng/ml 
 
8. Add FSK at 2 μM working 
concentration (0.2 μl/ml of a 10 mM 
stock) 
 
9. Add HGF at 50 ng/ml working 
concentration 
35 Stock collagen 
solution arrives 
highly viscous 
If the stock collagen 
solution is stored at 
temperatures below 2 °C, 
Warm the stock collagen solution to 
room temperature until the collagen 
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it can appear to have 
gelled 





Section A II 
Collagen 
precursor solution 
solidifies in the 
mixing tube. 
1. Solution mixing occurs 
too slowly 
 
2. The room temperature 
is too high. 
1. Before starting cool down all the 
reagents to 4 °C 
 







1. The absorbent paper 
wadding has poor contact 
with the collagen gel and 
so cannot remove water 
effectively 
 
2. As the paper wadding 
absorbs water, it expands 
and gets wedged in 
specimen tube, preventing 
further densification 
1. Remove the paper wadding from 
the specimen tube and flatten the 
end in contact with the collagen gel 
Once sufficiently flat, return to 
densification chamber 
 
2. Gently remove the paper wadding 
from the specimen tube and replace 







steps and removal 
of paper wadding, 
specimen tube is 
empty 
Collagen solution has 
been prematurely 
absorbed into the paper 
wadding before gelation 
1. Repeat process and extend time 
for collagen gelation from 30 min to 1 
h 
 
2. Test gelation by carefully pressing 
the metal spatula against the top 
surface. Only add paper wadding 





not attached to 
paper wadding on 
its final removal 
After the removal of the 
wadding, the collagen 
sheet remains at the 
The scaffold can be removed 
carefully using a pair of tweezers or 












chamber the lower 
part of the scaffold 
retains a gel-like 
structure 
Densification has been 
stopped prematurely, 
causing the lower part of 
the collagen sheet to 
retain a higher water 
content 
Return the scaffold to the 
densification chamber and continue 





Prior to collagen 
gelation, the level 
of the collagen 
solution has 
dropped. 
The collagen precursor 
solution is leaking out of 
the bottom of the funnel of 
the densification chamber. 
1. Keeping the chamber upright, 
carefully tighten the screws such that 
the base is firmly attached the funnel. 
 
2. Transfer an extra volume of 
collagen precursor solution until 
funnel is once again full. 
Step 39, 
Section B  
II 
The level of the 
collagen gel has 
dropped below the 
top of the metallic 
wire. 
The volume of collagen 
above the wire was unable 
to stop the collagen gel 
from dropping below the 
wire. 
1. Using scissors, remove a couple of 
millimetres of length from the top of 
the metallic wire. 
 
2. Repeat collagen gelling process. 
Step 39, 
Section B V 
The level of the 
collagen gel has 
not dropped to the 
top of the metallic 
wire. 
The paper towels at the 
base are not in sufficient 
contact with the gel and so 
water is not being drawn 
out.  
Repeat the process. When loosening 
the screws, do not displace the base 
away from the funnel, thereby 
keeping the paper towels in contact 
with the bottom of the collagen gel. 
Step 39, 
Section B 
V, VII, VIII 
Collagen gel has 
not densified after 
24 hours. 
There has been 
insufficient evaporation of 
water from the collagen 
gel to form a tube. 
1. Using sterile tweezers, repeat the 
process of peeling the collagen gel 
from the chamber walls. One should 
observe a 1-2 mm spacing between 
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the collagen gel and funnel walls. 
Continue densifying until tube forms. 
 
2. The humidity of the incubator may 
be high and so an insufficient volume 
of water has evaporated from the 
collagen gel. Continue Step VII, 
monitoring the evaporative process, 
until a collagen tube forms. 
Step 40, 






seeding, the cell 
suspension 
overspills from the 
scaffold 
1. The seeding volume is 
too big 
 
2. The seeding has 
occurred too close to the 
edge 
1. Immediately retrieve the spilled 
solution and seed it again onto the 
scaffold 
 
2. Reduce the total volume of cell 
suspension used during seeding 
Step 40, 
Section A 















1. Reduced incubation 
time preventing cell 
attachment  
 
2. Cell detachment during 
media change 
 
3. Low cell number. 
Optimal cell number and 
attachment potential may 
vary between lines  
 
4. Prolonged incubation 
leading to cell death and 
drying 
1. After seeding, increase the 
duration of the incubation step a 
further 30 minutes 
 
2. Add media very carefully. Tilt the 
plate and hold the pipette against the 
side of the well to avoid disrupting the 
Matrigel dome. Add the media slowly 
using a p1000 pipette 
 
3. Optimise the seeding density for 
each CO line 
 
4. Monitor the scaffolds closely after 




5. Small clump size 
leading to loss of cells 
through the pores of the 
PGA scaffold 
 
6. Single cells or very 
small clumps floating in 
the seeding solution and 
preventing attachment 
 
7. Remnants of EtOH or 
NaOH in PGA scaffolds 
leading to cell death in 
PGA scaffolds  
 
8. Excessive breaking of 
the CO clumps reducing 
cell viability 
 
media. Check the scaffolds every 30 
minutes to ensure the seeding 
solution has not evaporated 
 
5. Optimise the clump size when 
seeding PGA scaffolds 
 
6. Pipette more slowly and fewer 
times when breaking the COs into 
small clumps  
 
7. Increase the drying time to ensure 
all traces of NaOH and EtOH are 
gone (PGA scaffolds only) 
  
8. Use a P200 pipette instead of a 
p20 to break the CO clumps 
 
Pipette more slowly when breaking 
the CO clumps 
Step 40, 
Section B V 
CO clumps form 
organoid-like 3D 
structures rather 
than a monolayer 
CO clumps were not 
dissociated to a sufficiently 
small size 
Break clumps further, using a p10 





overflows from the 
construct lumen 
during seeding  




Dispense cells slowly, 
simultaneously withdrawing the 
needle from the tube lumen  
Step 40, 
Section A X 
Low cell density 
on the scaffold 
The cells may have been 
seeded too sparsely 



























Poor cell survival 
and/or expansion 
on the scaffold 
1. Cells are washed away 
during media change 
 
2. Y27632 not added to 
the media 
 
3. Suboptimal CO line  
 
2. Suboptimal collagen 
batch for collagen 
scaffolds 
 
5. Suboptimal quality of 
cytokines, media 
components or collagen 
stock  
 
6. Remnants of EtOH or 
NaOH in PGA scaffolds 
leading to cell death in 
PGA scaffolds  
1. Increase the media to 1 ml and 
change it very carefully every 4 days 
 
2. Ensure fresh Y27632 is added to 
the media when seeding 
 
3. All CO lines should express the 
biliary markers CK19, CK7, Sox9 and 
GGT (Fig. 6a and b) and display ALP 
and GGT activity (Fig. 6c and 6d). 
Healthy CO lines should be 
proliferating at a rate requiring 
passaging every five days (Fig. 5b, 
Image 1). Do not attempt scaffold 
seeding with a CO line that does not 
meet these criteria. See the 
Troubleshooting for steps 10, 12 and 
29 for recommendations on how to 






7. Prolonged incubation 
leading to cell death and 
drying  
4. Batch-test all new lots of collagen 
solution. (collagen scaffolds only) 
 
5. Store all stock solutions at 4 °C 
and do not use stock solutions made 
more than 3 months previously. 
Where applicable, do not use stock 
solutions beyond their expiry date.  
Store all cytokines at -80 °C 
 
6. Increase the drying time (70) to 
ensure all traces of NaOH and EtOH 
are gone (PGA scaffolds only) 
 
7. Monitor the scaffolds closely after 
seeding and before addition of 
media- check the scaffolds every 30 








1. The 4% (vol/vol) PFA 
may have degraded 
 
2. Samples may have 
been fixed for too long 
 
1. Store 4% (vol/vol) PFA at 4 °C and 
do not use for longer than one month 
 
2. Reduce fixation time. Do not 
attempt to fix too many samples at 







staining is poor 
The cells are not properly 
permeabilised, preventing 
adequate penetration of 
the antibody 
Increase the concentration of Triton 
X-100, e.g 0.3% (vol/vol) Triton X-










1. Blocking time may have 
been too short 
 
2. Secondary antibody 
incubation may have been 
too long 
1. Increase blocking time e.g. to one 
hour 
 
2. Incubate secondary antibodies for 
1 hour at room temperature instead 




DAPI staining is 
unclear 
Incubation with DAPI may 
not have been long 
enough 
Increase incubation with DAPI to 20 
or 30 minutes 
Step 41, 
Section B V 
COs do not 
dissociate into a 
single-cell 
suspension 
1. Cell clumping and/or 
poor viability 
 
2. CO clumps are not 
breaking up into single 
cells during the 5 minute 
incubation period 
 
1. Increase the concentration of 
DNase I in the accutase solution 
Ensure that all pipetting is done as 
slowly and carefully as possible 
2. Ensure the Accutase solution is 
pre-warmed 








Concentration of DNase I 
is too low 
Increase the concentration of DNase 
I, e.g. to 6 mg/ml 
 1 
ANTICIPATED RESULTS 2 
We describe a protocol for the isolation of primary biliary epithelial cells from a variety of clinical 3 
samples, their propagation as cholangiocyte organoids and the generation of bioengineered biliary 4 
tissue by seeding these organoids on PGA or densified collagen scaffolds. Our cholangiocyte isolation 5 
methods (ERCP, mechanical scraping, EPCAM sorting) result in a >95% pure (CK7+/CK19+) 6 
population of isolated cholangiocytes (Fig. 2e, 3d and 4e, respectively). Furthermore, 95% of plated 7 
samples derived from excised bile ducts (when appropriately flushed of bile after excision) and 100% 8 
of samples derived from gallbladders, liver biopsies and ERCP brushings yield robust CO lines within 9 
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5 days of initial plating (Supplementary Table 1). CO lines can be derived from EpCAM+ sorted liver 1 
samples with an approximate efficiency of 66% (Supplementary Table 1). While it is important to derive 2 
lines from fresh, highly viable primary tissue to ensure the most reliable results, robust, highly-3 
proliferative CO lines can also be derived from poor-quality samples with low cell numbers 4 
(supplemental Fig. 5). CO lines can subsequently be passaged approximately every 5 days and can 5 
typically be split in a 1:4-1:6 ratio for further expansion, analysis or cryopreservation.  6 
The resulting organoids consist of a near homogenous (>99%) population of cholangiocytes (Fig. 6e). 7 
They express biliary markers such as CK19, CK7, Sox9 and GGT (Fig. 6a) at levels comparable to 8 
primary tissue (Fig. 6b) in the absence of hepatic markers such as albumin (Fig. 6a). Furthermore, CO 9 
lines exhibit key cholangiocyte functions, such as alkaline phosphatase (ALP) and gamma-glutamyl 10 
transferase (GGT) activity (Fig. 6c and 6d). COs also display functional secretory capacity, as measured 11 
by the luminal secretion of rhodamine 123 (Sampaziotis et al; Nat. Med. (2017)- Fig. 2a-c) and bile acid 12 
transport, as measured by export of the fluorescently-labelled bile acid CLF (Sampaziotis et al; Nat. 13 
Med. (2017)- Fig. 2d-f). Additionally, COs respond appropriately to hormonal signals such as secretin 14 
and somatostatin ((Sampaziotis et al; Nat. Med. (2017)- Fig. 2i and 2j). For further validation, COs can 15 
be transplanted under the kidney capsule of immunocompromised mice where they form tubular 16 
structures retaining expression of biliary markers, such as CK7 and CK19 and are capable of surviving 17 
long-term 4 (Sampaziotis et al; Nat. Med. (2017) - Supplementary Fig. 7). 18 
COs can be seeded onto both densified collagen and PGA scaffolds to form bioengineered biliary 19 
tissue. Additionally, COs can be seeded onto the lumen of tubular densified collagen scaffolds (Fig. 20 
11e). The efficiency of cell attachment following seeding is variable between CO lines. However, 21 
following attachment the cells demonstrate a unique potential to expand and fully populate the scaffold.  22 
Therefore, the generation of confluent constructs is always possible by varying the time the scaffolds 23 
are maintained in culture. The resulting tissue expresses key cholangiocyte markers such as CK19 and 24 
CK7 (Fig. 11a, 11c and 11e) and exhibits biliary function such as GGT activity (Fig. 11b, 11d and 11f). 25 
These constructs can be used to successfully reconstruct or repair the biliary tree of 26 
immunocompromised mice4 (Sampaziotis et al; Nat. Med. (2017) - Fig. 4 and 6) while retaining the 27 
expression of biliary markers and function following transplantation (Sampaziotis et al; Nat. Med. (2017) 28 
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CO line derivation  14 
Supplementary figure 2: Derivation of intrahepatic organoids through EpCAM+ sorting 15 
 (a) Schematic representation of the optional EpCAM+ sorting step (procedure steps D III-DXXVI) for 16 
the derivation of intrahepatic COs. (b) Representative brightfield images of key EpCAM+ sorting steps. 17 
Numbers correspond to schematic stages in (a). 3: Liver tissue before enzymatic dissociation. 4: Liver 18 
tissue after enzymatic dissociation demonstrating release of cells in the medium and remnants of the 19 
extracellular matrix. 6: Single-cell suspension after filtration and before EpCAM+ sorting. Scale bars, 20 
100 μm. (c) Representative brightfield image of an organoid derived from a single EpCAM+ cell, 48 21 
hours after plating. Scale bar, 50 µm. 22 
Supplementary Figure 3: Enlarged images of COs before and after organoid breaking (from Figure 5) 23 
Enlarged images of COs before and after organoid breaking (from Figure 5). Enlarged brightfield images 24 
of figures 5b, image 1 and 5b, image 5. Scale bars, 100 μm. 25 
Supplementary figure 4: Representative images of cholangiocyte organoids 26 
Additional characterisation and troubleshooting of CO lines 27 
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(a) Representative brightfield images of healthy CO lines derived from all tissue types: 1: bile duct (BD), 1 
gallbladder (GB), Endoscopic Retrograde Cholangio-Pancreatography (ERCP), liver biopsy (biopsy) 2 
and EpCAM+ sorted cells (EpCAM). Scale bars- 200 μm. (b) Representative brightfield images of CO 3 
lines showing typical CO culture issues contrasted with optimal CO lines. Scale bars, 200 μm 4 
Supplementary figure 5: Derivation of a CO line from low cell numbers 5 
 (a) Representative brightfield images of a CBD CO line derived from ~3.0 x 103 viable cells/well (total: 6 
~2.0 x 104 viable cells). D0- D12: days after plating. P1: passage 1. (b) Graph illustrating cell number 7 
over time for the CBD line derived in (a) demonstrating appropriate expansion. 8 
Supplementary Figure 6: Gating strategy for flow cytometric analyses 9 
Representative flow cytometry plots showing gating strategy for all flow cytometric analyses. (a) 10 
Exclusion of debris. (b) Exclusion of doublets. (c) Secondary-only control to exclude negative 11 
population. (d) Representative C19+/CK7+ population. A minimum of 2 × 104 gated events were used 12 
for analysis. 13 
Supplementary Table 1: List of all CO lines derived since September 2016 14 
Table showing key details of all CO lines derived since September 2016: anonymised donor ID number; 15 
tissue type (bile duct (BD), gallbladder (GB) or intrahepatic ducts (IHD)); age; sex; donor type (if 16 
applicable) (donation after brain death (DBD) or donation after cardiac death (DCD); blood group; and 17 
the success of the line derivation 18 
Supplementary Table 2: List of antibodies used for flow cytometry and immunofluorescence  19 
Supplementary Software 1: CAD file for the base of the 3D-printed densification chamber used 20 
in Step 39, Section B 21 
Supplementary Software 2: CAD file for the funnel of the 3D-printed densification chamber used 22 
in Step 39, Section B 23 
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 24 
Figure. Legends 25 
Figure 1: Flowchart of key steps for the generation of bioengineered biliary tissue 26 
(a) Overview flowchart showing the 3 major protocol steps: cell isolation, scaffold preparation and 27 
generation of bioengineered biliary tissue. (b) Flowchart summarising the process of cell isolation 28 
from different biliary tissue samples with reference to the relevant protocol sections. (c) Flowchart 29 
illustrating the different types of biological or synthetic scaffolds used, with reference to the relevant 30 
protocol sections. (d) Flowchart summarising the seeding of acellular scaffolds with cholangiocyte 31 
organoid (CO) cells, with reference to the relevant protocol sections. 32 
 33 
Figure 2: Derivation of extrahepatic cholangiocyte organoids from extrahepatic biliary tissue 34 
(a) Schematic representation of key stages of the derivation of extrahepatic cholangiocyte organoids 35 
(ECO) from primary bile duct (BD) and gallbladder (GB) tissue (Procedure step 2, section A). (b, c) 36 
Representative images of key stages of the derivation of cholangiocytes from (b) primary BD and GB 37 
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(c) tissue. Numbers in (b) and (c) correspond to the schematic stages illustrated in (a): 1A(i), 1B(i): 1 
Resected biliary tissue prior to dissection. 1A(ii), 1B(ii): Tissue dissection. 1A(iii),1B(iii): Exposed 2 
luminal surface following dissection. 2: PBS wash. 3: Mechanical dissociation of the biliary epithelium. 3 
4: Primary cholangiocytes in suspension following dissociation. Scale bars: (b) Images 1(i) – 3, 1 cm. 4 
(c) Images 1(i) – 3:, 2 cm. (b) Image 4, (c) Image 4: 100 μm. (d) Representative brightfield images 5 
demonstrating key time points of ECO derivation. Scale bars, 200 μm. 1: Primary cholangiocytes 24 6 
hours after plating demonstrating the formation of early organoid structures. 2: ECOs following long 7 
term culture (passage 20). (e) Flow cytometry analysis of the primary cell suspension, demonstrating 8 
>90% cholangiocyte isolation efficiency (Steps 2 A I-A VIII; gating strategy demonstrated in 9 
supplementary figure 6).  10 
 11 
Figure 3: Derivation of extrahepatic cholangiocyte organoids through ERCP brushings 12 
(a) Schematic representation of ECO derivation from ERCP brushings (procedure step 2, section B). 13 
(b) Representative images of key stages of the derivation procedure. Numbers correspond to 14 
schematic stages in (a). 1: ERCP brush. 2: Media wash to dislodge the collected cholangiocytes from 15 
the brush. 3: Representative cell pellet after isolation. 4: Brightfield image of ERCP isolated 16 
cholangiocytes following plating.1-3: Scale bars, 1 cm. Scale bar, 200 μm. (c) Brightfield images 17 
demonstrating representative time points in the derivation of organoids from cholangiocytes obtained 18 
through ERCP brushings. 1: Primary cholangiocytes 24 hours after plating demonstrating the 19 
formation of early organoid structures. 2: Cholangiocyte organoids one week after plating. Scale bars, 20 
200 μm. (d) Flow cytometry analysis of the cell suspension obtained with through ERCP, 21 
demonstrating >90% cholangiocyte isolation efficiency (Steps 2 B I- BV; gating strategy demonstrated 22 
in supplementary figure 6). 23 
 24 
Figure 4: Derivation of intrahepatic organoids 25 
(a) Schematic representation of intrahepatic cholangiocyte organoid (ICOs) derivation (procedure step 26 
C). (b and c) Representative images of key stages of ICO derivation for (b) liver biopsies and (c) 27 
surgically resected liver tissue. Numbers correspond to schematic stages in (a). 1: Dissection of liver 28 
tissue. 2: Collection of dissected tissue. 3-4: Dissected tissue before (3) and after (4) centrifugation. 29 
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6(i): Representative image of liver tissue after embedding in Matrigel, prior to media addition. 1-6(i): 1 
Scale bars, 1 cm. 6(ii): Representative brightfield images of liver tissue after plating. Scale bar, 200 2 
μm. (d) Representative brightfield images demonstrating key time points of ICO derivation 1: ICO 3 
culture 5 days after plating demonstrating the emergence of an organoid from a segment of liver 4 
tissue. 2: Established ICO line (passage 20). Scale bars: 200 μm. (e) Flow cytometry analysis of ICO 5 
cells, demonstrating >95% cholangiocyte isolation efficiency (gating strategy in supplementary figure 6 
6). 7 
 8 
Figure 5: Passaging of cholangiocyte organoids 9 
(a) Schematic representation of the CO passaging procedure (procedure steps 15-30). (b) 10 
Representative images of key steps of the CO passaging procedure. Numbers correspond to 11 
schematic stages in (a). 1: Confluent COs prior to passaging. 4:  Representative organoid pellet 12 
yielding 9 organoid wells following plating (approximately 4.0 x 105 cells). 5: Suspension of COs after 13 
manual dissociation demonstrating representative clump size for passaging (approximately 30-100 14 
cells per clump) (procedure step 28). 7(i): COs immediately after plating (procedure steps 9-13) 15 
demonstrating that the majority of cells remain in small clumps and have not yet formed organoids at 16 
this stage. 7(ii) COs 24 hours after passaging, demonstrating that the majority of CO clumps have 17 
remodelled into organoids at this point. 1, 5, 7(i) and 7(ii): Scale bars, 100 μm. 4: Scale bar, 5 mm. 18 
 19 
Figure 6: Characterisation of cholangiocyte organoids 20 
(a) Immunofluorescence images demonstrating expression of key biliary markers in cholangiocyte 21 
organoids. Scale bar, 50 μm. (See table 1 for a detailed list of antibodies and concentrations used). 22 
(b) qRT–PCR confirming the expression of key biliary markers in ECOs compared to freshly isolated 23 
primary cholangiocytes (PC); n = 4 biological replicates. Centre line, median; box, interquartile range 24 
(IQR); whiskers, range (minimum to maximum). Values relative to the housekeeping gene HMBS 25 
(HydroxyMethylBilane Synthase).  # P > 0.05 (two-tailed Student’s t-test). (c) Cholangiocyte 26 
organoids demonstrate ALP activity. Scale bars, 100 μm. (d) GGT activity of cholangiocyte organoids 27 
measured in absorbance units (a.u.); n = 3; MEFs: mouse embryonic feeders, used as a negative 28 
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control. Error bars, s.d.; individual data points are demonstrated; ****P < 0.0001, two-tailed Student's 1 
t-test. GGT activity were assessed using a commercially available (MaxDiscovery gamma-Glutamyl 2 
Transferase (GGT) Enzymatic Assay) according to the manufacturer's instructions. (e) Flow 3 
cytometric analyses performed on COs after long term culture (20 passages) demonstrating >99% 4 
CK7+/CK19+ expression (gating strategy demonstrated in supplementary figure 6). 5 
 6 
Figure 7: Generation of densified collagen sheets  7 
 8 
(a) Schematic representation of the procedure for generating densified collagen sheets (procedure 9 
step 39, Section A). (b) Representative images of key stages of the collagen densification process. 10 
Numbers correspond to schematic stages in (a). 1: Specimen tube containing 5% collagen gel before 11 
densification (25 mm height). 2-3(i): Representative gel height following water absorption for 0 (2(i)), 12 
30 (2(ii)) and 60 (3(i)) minutes. 3(ii): Specimen tube containing fully densified collagen scaffold 13 
(indicated by the black arrow). 4: Removal of nylon mesh. 5: Representative image of the resulting 14 
densified collagen sheet. 1-4: Scale bars, 1 cm. 5: Scale bars, 5 mm.  15 
 16 
Figure 8: Generation of densified collagen tubes 17 
(a) Representative images of densification chamber assembly (Equipment Setup). 1: Densification 18 
chamber components: (i) Funnel, (ii) Base, (iii) wire, (iv) 25 G needle, (v) paper towels, (vi) M4 screws 19 
and (vii) nuts. 2:  Mounting of the rigid metal wire in the chamber base. 3: Addition of paper towels. 4: 20 
Addition of funnel. 5. Chamber assembly. Scale bars: 20 mm. (b) Schematic representation of 21 
collagen tube densification (step 39B I-IX). (c) Representative images of tube densification. Numbers 22 
correspond to schematic stages in (b). 1: Addition of collagen precursor solution. 2. Peeling of 23 
collagen from funnel walls. 3: Gel optimally positioned for evaporation. 4: Completion of densification. 24 
5. Removal of densified tube from wire. Scale bars, 15 mm. (d) Tube trimming following densification 25 
(step 39B, X-XV). 1: Collagen tubes immediately post-densification. 2. Washed tube. 3, 4: Tube 26 
trimming. 5. Trimmed tube with patent lumen (white dashed lines). Scale bars: (1)-(3), 2 cm; (4), 2mm; 27 




Figure 9: Seeding of flat densified collagen or PGA scaffolds 1 
(a) Schematic representation of the procedure for seeding densified collagen sheets and polyglycolic 2 
acid (PGA) scaffolds (procedure step 40, sections A and C, respectively). (b and c) Representative 3 
images of key stages of the seeding procedure for (b) densified collagen and (c) flat PGA scaffolds. 4 
Numbers correspond to schematic stages in (a). 1: Dried scaffold before seeding. 3(i): Addition of cell 5 
suspension on the scaffold at the start of seeding process. William’s E+ media with phenol red used 6 
for illustrative purposes. The use of phenol red in the media is optional. 3(ii): Scaffold after completion 7 
of seeding and prior to incubation. 5: Seeded scaffold following media addition. Scale bars, 1 cm. (d) 8 
Representative fluorescent image of a flat densified collagen scaffold confluently seeded with RFP+ 9 
COs. Scale bar, 100 µm (e) Representative fluorescent image of a PGA scaffold confluently seeded 10 
with GFP+ COs. Scale bar, 50 µm. 11 
 12 
Figure 10: Seeding of densified collagen tubular scaffolds 13 
(a) Schematic representation of densified collagen tube seeding (procedure step 40B). (b) 14 
Representative images of the seeding process. Image numbers refer to the corresponding stages 15 
illustrated in the schematic in (a). 2: Cannulation of tube lumen with 34 G needle. 3: Seeding of tube 16 
lumen with COs. Note the change in the tube colour as the lumen fills with Phenol Red containing 17 
media. Scale bars: (2), 1 mm;  (3), 5 mm. (c) Representative brightfield image of a CO-seeded 18 
densified collagen tube. Scale bar, 200 µm. (d) Representative fluorescent image of a densified 19 
collagen tube seeded with RFP+ COs. Scale bar, 200 µm. 20 
 21 
Figure 11: Characterisation of bioengineered biliary tissue 22 
(a) Immunofluorescence images demonstrating expression of key biliary markers in CO-seeded PGA 23 
scaffolds. Scale bar, 100 μm. (b) CO-seeded PGA scaffolds demonstrate GGT activity. A.U: 24 
absorbance units; n = 3; mouse embryonic feeders (MEFs) used as a negative control. Error bars, 25 
s.d.; individual data points are demonstrated; ****P < 0.0001, two-tailed Student's t-test. (c) 26 
Immunofluorescence images showing expression of key biliary markers in CO-seeded densified 27 
collagen sheets. Scale bar, 100 μm. (d) CO-seeded collagen scaffolds demonstrate GGT activity. 28 
77 
 
A.U.: absorbance units; n = 3; mouse embryonic feeders (MEFs) used as a negative control. Error 1 
bars, s.d.; individual data points are demonstrated; **P= 0.0055, two-tailed Student's t-test. (e) 2 
Immunofluorescence images showing expression of key biliary markers in CO-seeded densified 3 
collagen tubes. Scale bar, 100 μm. (d) CO-seeded collagen tubes demonstrate GGT activity. A.U.: 4 
absorbance units; n = 3; mouse embryonic feeders (MEFs) used as a negative control. Error bars, 5 
s.d.; individual data points are demonstrated; ****P= 0.0001, two-tailed Student's t-test. GGT activity 6 
was assessed using a commercially available kit (MaxDiscovery gamma-Glutamyl Transferase (GGT) 7 
Enzymatic Assay Kit) according to the manufacturer's instructions.  8 
